Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Liver Diseases

  Free Subscription


Articles published in J Hepatol

Retrieve available abstracts of 587 articles:
HTML format



Single Articles


    December 2022
  1. RUMGAY H, Arnold M, Ferlay J, Lesi O, et al
    Global burden of primary liver cancer in 2020 and predictions to 2040.
    J Hepatol. 2022;77:1598-1606.
    PubMed     Abstract available


  2. MITTEN EK, Baffy G
    Mechanotransduction in the pathogenesis of non-alcoholic fatty liver disease.
    J Hepatol. 2022;77:1642-1656.
    PubMed     Abstract available


  3. PAFILI K, Kahl S, Mastrototaro L, Strassburger K, et al
    Mitochondrial respiration is decreased in visceral but not subcutaneous adipose tissue in obese individuals with fatty liver disease.
    J Hepatol. 2022;77:1504-1514.
    PubMed     Abstract available


  4. MENDEZ-SANCHEZ N, Pal SC
    New terms for fatty liver disease other than MAFLD: Time for a reality check.
    J Hepatol. 2022;77:1716-1717.
    PubMed    


  5. BRANDEL V, Schimek V, Gober S, Hammond T, et al
    Hepatectomy-induced apoptotic extracellular vesicles stimulate neutrophils to secrete regenerative growth factors.
    J Hepatol. 2022;77:1619-1630.
    PubMed     Abstract available


  6. TIAN C, Min X, Zhao Y, Wang Y, et al
    MRG15 aggravates non-alcoholic steatohepatitis progression by regulating the mitochondrial proteolytic degradation of TUFM.
    J Hepatol. 2022;77:1491-1503.
    PubMed     Abstract available


  7. KIM BK, Tamaki N, Imajo K, Yoneda M, et al
    Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD.
    J Hepatol. 2022;77:1482-1490.
    PubMed     Abstract available


    November 2022
  8. MIESBACH W, Foster GR, Peyvandi F
    Liver-Related Aspects of Gene Therapy for Haemophilia: Call to Action for Collaboration between Haematologists and Hepatologists.
    J Hepatol. 2022 Nov 24:S0168-8278(22)03307-4. doi: 10.1016/j.jhep.2022.
    PubMed    


  9. NAHON P, Bamba-Funck J, Layese R, Trepo E, et al
    Integrating genetic variants into clinical models for hepatocellular carcinoma risk stratification in cirrhosis.
    J Hepatol. 2022 Nov 22:S0168-8278(22)03294-9. doi: 10.1016/j.jhep.2022.
    PubMed     Abstract available


  10. LOUVET A, Bourcier V, Archambeaud I, d'Alteroche L, et al
    Low alcohol consumption influences outcomes in individuals with alcohol-related compensated cirrhosis in a French multicenter cohort.
    J Hepatol. 2022 Nov 21:S0168-8278(22)03304-9. doi: 10.1016/j.jhep.2022.
    PubMed     Abstract available


  11. AJMERA V, Cepin S, Tesfai K, Hofflich H, et al
    A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes.
    J Hepatol. 2022 Nov 18:S0168-8278(22)03302-5. doi: 10.1016/j.jhep.2022.
    PubMed     Abstract available


  12. CHOI SJ, Choi SH, Kim DW, Kwag M, et al
    Value of threshold growth as a major diagnostic feature of hepatocellular carcinoma in LI-RADS.
    J Hepatol. 2022 Nov 16:S0168-8278(22)03297-4. doi: 10.1016/j.jhep.2022.
    PubMed     Abstract available


  13. CHOLANKERIL G, Kramer JR, Chu J, Yu X, et al
    Longitudinal changes in fibrosis markers are associated with risk of cirrhosis and hepatocellular carcinoma in non-alcoholic fatty liver disease.
    J Hepatol. 2022 Nov 16:S0168-8278(22)03299-8. doi: 10.1016/j.jhep.2022.
    PubMed     Abstract available


  14. LUO L, Yao X, Yang W
    Biejia-Ruangan compound and incidence of hepatocellular carcinoma.
    J Hepatol. 2022 Nov 16:S0168-8278(22)03305-0. doi: 10.1016/j.jhep.2022.
    PubMed    


  15. BAJAJ JS
    Albumin for Liver-Brain Outcome Improvement Across Different Situations in Cirrhosis.
    J Hepatol. 2022 Nov 15. pii: S0168-8278(22)03298.
    PubMed    


  16. SANYAL AJ, Foucquier J, Younossi ZM, Harrison SA, et al
    Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores.
    J Hepatol. 2022 Nov 11. pii: S0168-8278(22)03293.
    PubMed     Abstract available


  17. CHEN S, Lu Z, Jia H, Yang B, et al
    Hepatocyte-specific Mas activation enhances lipophagy and fatty acid oxidation to protect against acetaminophen-induced hepatotoxicity in mice.
    J Hepatol. 2022 Nov 9. pii: S0168-8278(22)03285.
    PubMed     Abstract available


  18. SHEN W, Middleton MS, Cunha GM, Delgado TI, et al
    Changes in abdominal adipose tissue depots accessed by MRI correlate with hepatic histologic improvement in non-alcoholic steatohepatitis.
    J Hepatol. 2022 Nov 8. pii: S0168-8278(22)03284.
    PubMed     Abstract available


  19. ZHANG X, Song J, Zhang Y, Wen B, et al
    Baveno VII algorithm outperformed other models in ruling out high-risk varices in individuals with HBV-related cirrhosis.
    J Hepatol. 2022 Nov 7. pii: S0168-8278(22)03287.
    PubMed     Abstract available


  20. RATZIU V, Harrison SA, Loustaud-Ratti V, Bureau C, et al
    Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH.
    J Hepatol. 2022 Nov 2. pii: S0168-8278(22)03160.
    PubMed     Abstract available


  21. TRANAH TH, Ballester MP, Carbonell-Asins JA, Jalan R, et al
    Reply to 'Ammonia and prognosis of cirrhosis: a new perspective for identifying high risk patients'.
    J Hepatol. 2022 Nov 2. pii: S0168-8278(22)03162.
    PubMed    


  22. VAN KLEEF LA, Kavousi M, de Knegt RJ
    Reply to: "Liver stiffness, fatty liver disease and atrial fibrillation in the Rotterdam study: Some issues".
    J Hepatol. 2022;77:1467-1468.
    PubMed    


  23. PETERMANN-ROCHA F, Ho FK, Pell JP
    Reply to: "Associations of muscle mass and grip strength with severe NAFLD: A prospective study of 333,295 UK Biobank participants".
    J Hepatol. 2022;77:1454-1455.
    PubMed    


  24. ENGELMANN C, Habtesion A, Hassan M, Kerbert AJ, et al
    Combination of G-CSF and a TLR4 inhibitor reduce inflammation and promote regeneration in a mouse model of ACLF.
    J Hepatol. 2022;77:1325-1338.
    PubMed     Abstract available


  25. ALLEN AM, Therneau TM, Ahmed OT, Gidener T, et al
    Clinical course of non-alcoholic fatty liver disease and the implications for clinical trial design.
    J Hepatol. 2022;77:1237-1245.
    PubMed     Abstract available


  26. TRIPATHI M, Singh BK, Zhou J, Tikno K, et al
    Vitamin B12 and folate decrease inflammation and fibrosis in NASH by preventing syntaxin 17 homocysteinylation.
    J Hepatol. 2022;77:1246-1255.
    PubMed     Abstract available


  27. JIN B, Du S, Yang H
    HBsAg seroclearance reduces the risk of late recurrence in HBV-related HCC.
    J Hepatol. 2022;77:1469-1470.
    PubMed    


  28. TSAI WC, Yu ML, Dai CY
    Liver stiffness, fatty liver disease and atrial fibrillation in the Rotterdam study: Some issues.
    J Hepatol. 2022;77:1466-1467.
    PubMed    


  29. NAOUMOV NV, Brees D, Loeffler J, Chng E, et al
    Digital pathology with artificial intelligence analyses provides greater insights into treatment-induced fibrosis regression in NASH.
    J Hepatol. 2022;77:1399-1409.
    PubMed     Abstract available


  30. HENDRIKX T, Porsch F, Kiss MG, Rajcic D, et al
    Soluble TREM2 levels reflect the recruitment and expansion of TREM2(+) macrophages that localize to fibrotic areas and limit NASH.
    J Hepatol. 2022;77:1373-1385.
    PubMed     Abstract available


  31. DIAO YK, Kong QY, Yang T
    HBsAg seroclearance and reduction in late recurrence of HBV-related HCC: Causality or co-existence?
    J Hepatol. 2022;77:1468-1469.
    PubMed    


  32. CHEN L, Fan Z, Lv G
    Associations of muscle mass and grip strength with severe NAFLD: A prospective study of 333,295 UK Biobank participants.
    J Hepatol. 2022;77:1453-1454.
    PubMed    


  33. TRANAH TH, Ballester MP, Carbonell-Asins JA, Jalan R, et al
    Reply to 'The possible link between higher ammonia levels associated with non-alcoholic fatty liver related cirrhosis and diabetes: are we missing chronic kidney disease?'
    J Hepatol. 2022 Nov 1. pii: S0168-8278(22)03161.
    PubMed    


    October 2022
  34. SPOSITO C, Ratti F, Cucchetti A, Ardito F, et al
    Survival benefit of adequate lymphadenectomy in patients undergoing liver resection for clinically node negative intrahepatic cholangiocarcinoma.
    J Hepatol. 2022 Oct 31. pii: S0168-8278(22)03158.
    PubMed     Abstract available


  35. NOUREDDIN M, Harrison SA
    NASH Cirrhosis Trials And Major Adverse Liver Outcomes: Big Data Needed.
    J Hepatol. 2022 Oct 31. pii: S0168-8278(22)03159.
    PubMed    


  36. CABIBBO G, Bruix J
    Radiological endpoints as surrogates for survival benefit in Hepatocellular Carcinoma trials: all that glitters is not gold.
    J Hepatol. 2022 Oct 30. pii: S0168-8278(22)03155.
    PubMed    


  37. LI B, Hong C, Fan Z, Cai S, et al
    Prognostic and therapeutic significance of microbial cell-free DNA in plasma of people with acutely decompensated cirrhosis.
    J Hepatol. 2022 Oct 26. pii: S0168-8278(22)03144.
    PubMed     Abstract available


  38. PRYKE R, Guha IN
    Time to focus chronic liver diseases back into the community: A review of primary care hepatology tools, pathways of care and reimbursement mechanisms.
    J Hepatol. 2022 Oct 22. pii: S0168-8278(22)03146.
    PubMed     Abstract available


  39. LI T, Lu Z
    Factor VIII as a potential predictor of recurrent thrombosis in patients with non-cirrhotic portal vein thrombosis.
    J Hepatol. 2022 Oct 11. pii: S0168-8278(22)03136.
    PubMed    


  40. PERICAS JM, Tacke F, Anstee QM, Di Prospero NA, et al
    Platform trials to overcome major shortcomings of traditional clinical trials in non-alcoholic steatohepatitis? Pros and Cons.
    J Hepatol. 2022 Oct 7. pii: S0168-8278(22)03131.
    PubMed     Abstract available


  41. TSAI PC, Kuo HT, Hung CH, Tseng KC, et al
    Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan.
    J Hepatol. 2022 Oct 5. pii: S0168-8278(22)03129.
    PubMed     Abstract available


  42. BITTENCOURT PL, Oliveira CP, Codes L, Ferraz MLG, et al
    Internet search engines and social media are improving awareness on non-alcoholic fatty liver disease in Brazil.
    J Hepatol. 2022;77:1217-1219.
    PubMed    


  43. PEISELER M, Schwabe R, Hampe J, Kubes P, et al
    Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits.
    J Hepatol. 2022;77:1136-1160.
    PubMed     Abstract available



  44. EASL Clinical Practice Guidelines on the management of cystic liver diseases.
    J Hepatol. 2022;77:1083-1108.
    PubMed     Abstract available


  45. DE GOTTARDI A, Sempoux C, Berzigotti A
    Porto-sinusoidal vascular disorder.
    J Hepatol. 2022;77:1124-1135.
    PubMed     Abstract available


  46. VAN KLEEF LA, Lu Z, Arfan Ikram M, de Groot NMS, et al
    Liver stiffness not fatty liver disease is associated with atrial fibrillation: The Rotterdam study.
    J Hepatol. 2022;77:931-938.
    PubMed     Abstract available


  47. STAUFER K, Huber-Schonauer U, Strebinger G, Pimingstorfer P, et al
    Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease.
    J Hepatol. 2022;77:918-930.
    PubMed     Abstract available


  48. BASTATI N, Beer L, Ba-Ssalamah A, Poetter-Lang S, et al
    Gadoxetic acid-enhanced MRI-derived functional liver imaging score (FLIS) and spleen diameter predict outcomes in ACLD.
    J Hepatol. 2022;77:1005-1013.
    PubMed     Abstract available


    September 2022
  49. ELFEKI MA, Singal AK
    The possible link between higher ammonia levels associated with non-alcoholic fatty liver related cirrhosis and diabetes: are we missing chronic kidney disease?
    J Hepatol. 2022 Sep 30. pii: S0168-8278(22)03125.
    PubMed    


  50. WANG Y, Hu M, Yang H
    Cirrhosis is an independent predictor for COVID-19 mortality: A meta-analysis of confounding cofactors-controlled data.
    J Hepatol. 2022 Sep 27. pii: S0168-8278(22)03122.
    PubMed    


  51. REINIS J, Petrenko O, Simbrunner B, Hofer BS, et al
    Assessment of portal hypertension severity using machine learning models in patients with compensated cirrhosis.
    J Hepatol. 2022 Sep 21. pii: S0168-8278(22)03119.
    PubMed     Abstract available


  52. FAGAN A, Gavis EA, Gallagher ML, Mousel T, et al
    A double-blind randomized placebo-controlled trial of albumin in patients with hepatic encephalopathy: HEAL study.
    J Hepatol. 2022 Sep 21. pii: S0168-8278(22)03116.
    PubMed     Abstract available


  53. RIDOLA L, Riggio O
    Ammonia and prognosis of cirrhosis: a new perspective for identifying high risk patients.
    J Hepatol. 2022 Sep 20. pii: S0168-8278(22)03112.
    PubMed    


  54. ARECHEDERRA M, Fernandez-Barrena MG
    Hepatic progenitor cells, senescence and IL6 as the main players in combined hepatocellular-cholangiocarcinoma development.
    J Hepatol. 2022 Sep 20. pii: S0168-8278(22)03114.
    PubMed    


  55. ZANETTO A, Pelizzaro F, Campello E, Bulato C, et al
    Severity of systemic inflammation is the main predictor of ACLF and bleeding in patients with acutely decompensated cirrhosis.
    J Hepatol. 2022 Sep 20. pii: S0168-8278(22)03110.
    PubMed     Abstract available


  56. KUDO M, Finn RS, Qin S, Han KH, et al
    Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study.
    J Hepatol. 2022 Sep 20. pii: S0168-8278(22)03111.
    PubMed     Abstract available


  57. MARTIN-NAVARRO L, de Andrea C, Sangro B, Argemi J, et al
    In situ detection of vaccine mRNA in the cytoplasm of hepatocytes during COVID19 vaccine-related hepatitis.
    J Hepatol. 2022 Sep 15. pii: S0168-8278(22)03076.
    PubMed    


  58. MAIWALL R, Deshmukh A, Sarin SK
    Reply to: "Response to: A randomized-controlled trial comparing 20% albumin to plasmalyte in patients with cirrhosis and sepsis-induced hypotension [ALPS trial]".
    J Hepatol. 2022 Sep 13. pii: S0168-8278(22)03069.
    PubMed    


  59. PARIKH ND, Tayob N, Singal AG
    Blood-based biomarkers for hepatocellular carcinoma screening: Approaching the end of the ultrasound era?
    J Hepatol. 2022 Sep 8. pii: S0168-8278(22)03067.
    PubMed     Abstract available


  60. KAZANKOV K, Novelli S, Chatterjee DA, Phillips A, et al
    Evaluation of CirrhoCare(R) - A digital-health solution for home management of patients with cirrhosis.
    J Hepatol. 2022 Sep 7. pii: S0168-8278(22)03066.
    PubMed     Abstract available


  61. PATERNOSTRO R, Kwanten WJ, Reiberger T
    Portal hypertension is a key determinant of the risk for liver-related events in non-alcoholic fatty liver disease.
    J Hepatol. 2022 Sep 4. pii: S0168-8278(22)03062.
    PubMed    


  62. SEMMLER G, Lens S, Meyer EL, Baiges A, et al
    Non-invasive tests for clinically significant portal hypertension after HCV cure.
    J Hepatol. 2022 Sep 2. pii: S0168-8278(22)03056.
    PubMed     Abstract available


  63. LUJAMBIO A, Sarobe P
    Metformin keeps CD8(+) T cells active and moving in NASH-HCC immunotherapy.
    J Hepatol. 2022;77:593-595.
    PubMed    


  64. MANDORFER M, Scheiner B, Lisman T
    On coagulation in advanced chronic liver disease and the origin of freshwater eels.
    J Hepatol. 2022;77:886-887.
    PubMed    


  65. LANGER MM, Eickelmann C, Kleinbongard P, Lange CM, et al
    Impaired mitochondrial complex IV respiration in peripheral blood mononuclear cells discriminates acute-on-chronic liver failure from acute decompensation.
    J Hepatol. 2022;77:874-876.
    PubMed    


  66. CHEN ZX, Liu SY, Tong XM
    Preoperative prediction of microvascular invasion: Is invasive biopsy of HCC necessary?
    J Hepatol. 2022;77:892-893.
    PubMed    


  67. GREUTER T, Yaqoob U, Gan C, Jalan-Sakrikar N, et al
    Mechanotransduction-induced glycolysis epigenetically regulates a CXCL1-dominant angiocrine signaling program in liver sinusoidal endothelial cells in vitro and in vivo.
    J Hepatol. 2022;77:723-734.
    PubMed     Abstract available


  68. CHOI SE, Hwang Y, Lee SJ, Jung H, et al
    Mitochondrial protease ClpP supplementation ameliorates diet-induced NASH in mice.
    J Hepatol. 2022;77:735-747.
    PubMed     Abstract available


  69. BASELLI GA, Jamialahmadi O, Pelusi S, Ciociola E, et al
    Rare ATG7 genetic variants predispose patients to severe fatty liver disease.
    J Hepatol. 2022;77:596-606.
    PubMed     Abstract available


  70. WABITSCH S, McCallen JD, Kamenyeva O, Ruf B, et al
    Metformin treatment rescues CD8(+) T-cell response to immune checkpoint inhibitor therapy in mice with NAFLD.
    J Hepatol. 2022;77:748-760.
    PubMed     Abstract available


  71. XIE J, Lu L, Chen Y, Xu L, et al
    A simpler definition of MAFLD better predicts long-term all-cause mortality in American adults.
    J Hepatol. 2022;77:877-879.
    PubMed    


  72. BAIGES A, Procopet B, Silva-Junior G, Llop E, et al
    Incidence and factors predictive of recurrent thrombosis in patients with non-cirrhotic portal vein thrombosis.
    J Hepatol. 2022 Sep 1. pii: S0168-8278(22)03054.
    PubMed     Abstract available


  73. YANG H, Bae SH, Jang JW
    Reply to: 'A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: considerations'.
    J Hepatol. 2022 Sep 1. pii: S0168-8278(22)03057.
    PubMed    


    August 2022
  74. WHITFIELD JB, Morgan TR, Seth D
    Reply to: External validation of a genetic risk score that predicts development of alcohol-related cirrhosis.
    J Hepatol. 2022 Aug 30. pii: S0168-8278(22)03055.
    PubMed    


  75. WANG Q, Zhao H, Deng Y, Zheng H, et al
    Validation of Baveno VII criteria for recompensation in entecavir-treated individuals with hepatitis B-related decompensated cirrhosis.
    J Hepatol. 2022 Aug 26. pii: S0168-8278(22)03019.
    PubMed     Abstract available


  76. ROSENBERG N, Van Haele M, Lanton T, Brashi N, et al
    Combined hepatocellular-cholangiocarcinoma derives from liver progenitor cells and depends on senescence and IL6 trans-signaling.
    J Hepatol. 2022 Aug 18. pii: S0168-8278(22)02995.
    PubMed     Abstract available


  77. SALEM R, Greten TF
    Interventional radiology meets immuno-oncology for hepatocellular carcinoma.
    J Hepatol. 2022 Aug 18. pii: S0168-8278(22)03003.
    PubMed     Abstract available


  78. LABENZ C, Arslanow A, Lammert F, Galle PR, et al
    Reply to: "an individualized cirrhosis screening strategy might be more cost-effective in the general population".
    J Hepatol. 2022 Aug 18. pii: S0168-8278(22)03006.
    PubMed    


  79. CALDERARO J, Di Tommaso L, Maille P, Beaufrere A, et al
    Nestin as a diagnostic and prognostic marker for combined hepatocellular-cholangiocarcinoma.
    J Hepatol. 2022 Aug 17. pii: S0168-8278(22)02983.
    PubMed     Abstract available


  80. BASELLI G, Romeo S, Valenti L
    Reply to: "Lack of hepatic autophagy promotes severity of liver injury but not steatosis": ATG7 genetic variants behave as fatty liver disease progression modifiers.
    J Hepatol. 2022 Aug 17. pii: S0168-8278(22)02992.
    PubMed    


  81. JI D, Chen Y, Bi J, Shang Q, et al
    Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B.
    J Hepatol. 2022 Aug 16. pii: S0168-8278(22)02982.
    PubMed     Abstract available


  82. JOHN BV, Ferreira RD, Doshi A, Kaplan DE, et al
    Third dose of COVID-19 mRNA vaccine appears to overcome vaccine hyporesponsiveness in patients with cirrhosis.
    J Hepatol. 2022 Aug 16. pii: S0168-8278(22)03002.
    PubMed     Abstract available


  83. BAILEY AL, Diamond MS
    Hepatopathology of flaviviruses.
    J Hepatol. 2022 Aug 15. pii: S0168-8278(22)00339.
    PubMed    


  84. AGGARWAL A, Montanari NR, Ramirez R, Diehl L, et al
    Reply to: Hepatocyte expression of hepatitis B surface and core antigens across phases of chronic hepatitis B infection.
    J Hepatol. 2022 Aug 14. pii: S0168-8278(22)03000.
    PubMed    


  85. BOWLUS CL, Levy C, Hirschfield GM
    Reply to: "Seladelpar in patients with primary biliary cholangitis: Need for a closer look!"
    J Hepatol. 2022 Aug 14. pii: S0168-8278(22)02990.
    PubMed    


  86. DEGASPERI E, Anolli MP, Uceda Renteria SC, Sambarino D, et al
    Bulevirtide monotherapy for 48 Weeks in hdv patients with compensated cirrhosis and clinically significant portal hypertension.
    J Hepatol. 2022 Aug 13. pii: S0168-8278(22)02980.
    PubMed     Abstract available


  87. GEHRING AJ, MacParland SA
    Intrahepatic T cells with NK-like properties: expanding the repertoire of lymphocytes sensitive to bystander activation.
    J Hepatol. 2022 Aug 12. pii: S0168-8278(22)02985.
    PubMed    


  88. ALAZAWI W
    Myeloid XBP1 links lipid overload with inflammation in NASH: Do advances in basic science have clinical potential?
    J Hepatol. 2022;77:290-292.
    PubMed    



  89. EASL Clinical Practice Guidelines on haemochromatosis.
    J Hepatol. 2022;77:479-502.
    PubMed     Abstract available


  90. SCHOMERUS G, Leonhard A, Manthey J, Morris J, et al
    The stigma of alcohol-related liver disease and its impact on healthcare.
    J Hepatol. 2022;77:516-524.
    PubMed     Abstract available


  91. BLACK SM, Zhang Z, Han Y, Zeng C, et al
    Reply to: "Protection against acetaminophen-induced liver injury with MG53: Muscle-liver axis and necroptosis".
    J Hepatol. 2022;77:562-563.
    PubMed    


  92. BUGIANESI E, Petta S
    NAFLD/NASH.
    J Hepatol. 2022;77:549-550.
    PubMed    


  93. BJORNSSON HK, Bjornsson ES
    Reply to: "Can azathioprine prevent infliximab-induced liver injury?"
    J Hepatol. 2022;77:555-556.
    PubMed    


  94. ROWE IA, D'Amico G
    Taking a risk-based approach to testing for liver disease in primary care, a step in the right direction.
    J Hepatol. 2022;77:293-295.
    PubMed    


  95. JAESCHKE H, Umbaugh DS
    Protection against acetaminophen-induced liver injury with MG53: Muscle-liver axis and necroptosis.
    J Hepatol. 2022;77:560-562.
    PubMed    


  96. ABERG F, Luukkonen PK, But A, Salomaa V, et al
    Development and validation of a model to predict incident chronic liver disease in the general population: The CLivD score.
    J Hepatol. 2022;77:302-311.
    PubMed     Abstract available


  97. MEUNIER L, Malezieux E, Bozon A, Meszaros M, et al
    Can azathioprine prevent infliximab-induced liver injury?
    J Hepatol. 2022;77:553-555.
    PubMed    


    July 2022
  98. TRANAH TH, Ballester MP, Carbonell-Asins JA, Ampuero J, et al
    Plasma ammonia levels predict hospitalisation with liver-related complications and mortality in clinically stable outpatients with cirrhosis.
    J Hepatol. 2022 Jul 21. pii: S0168-8278(22)02947.
    PubMed     Abstract available


  99. MARJOT T, Eberhardt CS, Boettler T, Belli LS, et al
    Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: an updated EASL position paper.
    J Hepatol. 2022 Jul 19. pii: S0168-8278(22)02942.
    PubMed    


  100. NELL P, Kattler K, Feuerborn D, Hellwig B, et al
    Identification of an FXR-modulated liver-intestine hybrid state in iPSC-derived hepatocyte-like cells.
    J Hepatol. 2022 Jul 18. pii: S0168-8278(22)02943.
    PubMed     Abstract available


  101. LIU SY, Yuan C, Tong XM
    Antiviral therapy, HBsAg seroclearance and late recurrence of Hepatitis B-related hepatocellular carcinoma.
    J Hepatol. 2022 Jul 18. pii: S0168-8278(22)02938.
    PubMed    


  102. ZHAO S, Liao X, Fan R
    An individualized cirrhosis screening strategy might be more cost-effective in the general population.
    J Hepatol. 2022 Jul 14. pii: S0168-8278(22)02937.
    PubMed    


  103. MAIMONE S, Tripodi VF, Mazzeo AT
    Response to: A randomized-controlled trial comparing 20% albumin to plasmalyte in patients with cirrhosis and sepsis-induced hypotension [ALPS trial].
    J Hepatol. 2022 Jul 7. pii: S0168-8278(22)02926.
    PubMed    


  104. FONTANELLAS A, Avila MA
    Hydroxymethylbilane synthase (aka porphobilinogen deaminase): a novel metabolic tumor suppressor gene in hepatocellular carcinoma.
    J Hepatol. 2022 Jul 4. pii: S0168-8278(22)02921.
    PubMed    


  105. BARCENA-VARELA M
    Revealing anti-PD-1 resistance mechanisms in HCC: A path towards novel combination immunotherapies.
    J Hepatol. 2022;77:9-11.
    PubMed    


  106. GUO B, Zhou J, Zhao X
    Reply to: "Comment on "Exposure to air pollution is associated with an increased risk of metabolic dysfunction-associated fatty liver disease"".
    J Hepatol. 2022;77:260-262.
    PubMed    


  107. YU M, Chen Z, Zhou Q, Zhang B, et al
    PARG inhibition limits HCC progression and potentiates the efficacy of immune checkpoint therapy.
    J Hepatol. 2022;77:140-151.
    PubMed     Abstract available


  108. MARTI-AGUADO D, Clemente-Sanchez A, Bataller R
    Cigarette smoking and liver diseases.
    J Hepatol. 2022;77:191-205.
    PubMed     Abstract available


  109. CHEN YS, Hung YM, Wei JC
    Comment on "Exposure to air pollution is associated with an increased risk of metabolic dysfunction-associated fatty liver disease".
    J Hepatol. 2022;77:259-260.
    PubMed    


  110. MENDEZ-SANCHEZ N, Maris-Gil S, Alonso-Rivera CG
    Latin American Association of Pediatrics (ALAPE) endorses the MAFLD definition of fatty liver disease.
    J Hepatol. 2022;77:249.
    PubMed    


    June 2022
  111. VERMA AK, Sharma A, Subramaniyam N, Gandhi CR, et al
    Augmenter of liver regeneration: mitochondrial function and steatohepatitis.
    J Hepatol. 2022 Jun 28. pii: S0168-8278(22)00413.
    PubMed     Abstract available


  112. CORPECHOT C, Carrat F, Gaouar F, Chau F, et al
    Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis.
    J Hepatol. 2022 Jun 28. pii: S0168-8278(22)00411.
    PubMed     Abstract available


  113. HUANG B, Lyu Z, Qian Q, Chen Y, et al
    NUDT1 promotes the accumulation and longevity of CD103(+) TRM cells in primary biliary cholangitis.
    J Hepatol. 2022 Jun 23. pii: S0168-8278(22)00408.
    PubMed     Abstract available


  114. ALVISI G, Termanini A, Soldani C, Portale F, et al
    Multimodal single-cell profiling of intrahepatic cholangiocarcinoma defines hyperactivated Tregs as a potential therapeutic target.
    J Hepatol. 2022 Jun 20. pii: S0168-8278(22)00370.
    PubMed     Abstract available


  115. JEPSEN P, Reeves H
    Signed, SEALed, detected I'm your patient with advanced fibrosis or cirrhosis!
    J Hepatol. 2022 Jun 20. pii: S0168-8278(22)00369.
    PubMed    


  116. BEAUFRERE A, Vilgrain V, Paradis V
    Reply to chao Li et al., Zi-Xiang Chen et al. and Ke-Chun Wang et al.: "Gene expression signature as a surrogate marker of microvascular invasion on routine hepatocellular carcinoma biopsies".
    J Hepatol. 2022 Jun 19. pii: S0168-8278(22)00374.
    PubMed    


  117. SCHLEGEL A, Porte RJ, Dutkowski P
    Corrigendum to 'Protective mechanisms and current clinical evidence of hypothermic oxygenated machine perfusion (HOPE) in preventing post-transplant cholangiopathy' [J Hepatol 76 (2022) 1330-1347].
    J Hepatol. 2022 Jun 16. pii: S0168-8278(22)00353.
    PubMed    


  118. BRESCIANI N, Demagny H, Lemos V, Pontanari F, et al
    SLC25A47 is a novel determinant of hepatic mitochondrial function implicated in liver fibrosis.
    J Hepatol. 2022 Jun 14. pii: S0168-8278(22)00364.
    PubMed     Abstract available


  119. LURZ E, Lenz D, Bufler P, Fichtner A, et al
    Letter to the editor - A peditatric hepatologists' perspective.
    J Hepatol. 2022 Jun 14. pii: S0168-8278(22)00363.
    PubMed    


  120. JOHANSEN S, Thiele M, Juel HB, Hansen T, et al
    External validation of a genetic risk score that predicts development of alcohol-related cirrhosis.
    J Hepatol. 2022 Jun 13. pii: S0168-8278(22)00365.
    PubMed    


  121. SALEM R, Tselikas L, De Baere T
    Interventional treatment of hepatocellular carcinoma.
    J Hepatol. 2022 Jun 12. pii: S0168-8278(22)00229.
    PubMed    


  122. TANG Y, Chen Y, Chen HN
    A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: considerations.
    J Hepatol. 2022 Jun 8. pii: S0168-8278(22)00354.
    PubMed    



  123. EASL Clinical Practice Guidelines on the management of hepatic encephalopathy.
    J Hepatol. 2022 Jun 7. pii: S0168-8278(22)00346.
    PubMed    


  124. GRAVELY AK, Vibert E, Sapisochin G
    Surgical treatment of intrahepatic cholangiocarcinoma.
    J Hepatol. 2022 Jun 5. pii: S0168-8278(22)00017.
    PubMed    


  125. ANSTEE QM, Castera L, Loomba R
    Impact of non-invasive biomarkers on hepatology practice: Past, present and future.
    J Hepatol. 2022;76:1362-1378.
    PubMed     Abstract available


  126. CALDERARO J, Seraphin TP, Luedde T, Simon TG, et al
    Artificial intelligence for the prevention and clinical management of hepatocellular carcinoma.
    J Hepatol. 2022;76:1348-1361.
    PubMed     Abstract available


  127. CARACENI P, O'Brien A, Gines P
    Long-term albumin treatment in patients with cirrhosis and ascites.
    J Hepatol. 2022;76:1306-1317.
    PubMed     Abstract available


  128. LISMAN T, Caldwell SH, Intagliata NM
    Haemostatic alterations and management of haemostasis in patients with cirrhosis.
    J Hepatol. 2022;76:1291-1305.
    PubMed     Abstract available


  129. TERRAULT NA, Dufour JF, Schwabe RF, Wong VW, et al
    Breakthroughs in hepatology.
    J Hepatol. 2022;76:1247-1248.
    PubMed    


  130. GARDIN A, Remih K, Gonzales E, Andersson ER, et al
    Modern therapeutic approaches to liver-related disorders.
    J Hepatol. 2022;76:1392-1409.
    PubMed     Abstract available


  131. BAJAJ JS, Ng SC, Schnabl B
    Promises of microbiome-based therapies.
    J Hepatol. 2022;76:1379-1391.
    PubMed     Abstract available


  132. GE J, Kim WR, Lai JC, Kwong AJ, et al
    "Beyond MELD" - Emerging strategies and technologies for improving mortality prediction, organ allocation and outcomes in liver transplantation.
    J Hepatol. 2022;76:1318-1329.
    PubMed     Abstract available


  133. RATZIU V, Francque S, Sanyal A
    Breakthroughs in therapies for NASH and remaining challenges.
    J Hepatol. 2022;76:1263-1278.
    PubMed     Abstract available


    May 2022
  134. VILLANUEVA C, Torres F, Sarin SK, Shah HA, et al
    Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis.
    J Hepatol. 2022 May 31. pii: S0168-8278(22)00336.
    PubMed     Abstract available


  135. MOLINA L, Zhu J, Trepo E, Bayard Q, et al
    Biallelic hydroxymethylbilane synthase inactivation defines a homogenous clinico-molecular subtype of hepatocellular carcinoma.
    J Hepatol. 2022 May 27. pii: S0168-8278(22)00333.
    PubMed     Abstract available


  136. KOH JY, Rha MS, Choi SJ, Lee HS, et al
    Identification of a distinct NK-like hepatic T-cell population activated by NKG2C in a TCR-independent manner.
    J Hepatol. 2022 May 26. pii: S0168-8278(22)00335.
    PubMed     Abstract available


  137. POURIKI S, Alexopoulos T, Vasilieva L, Vrioni G, et al
    Rectal colonization by resistant bacteria is associated with infection by the colonizing strain and high mortality in decompensated cirrhosis.
    J Hepatol. 2022 May 25. pii: S0168-8278(22)00328.
    PubMed    


  138. YOO S, Kim JY, Lim YS, Han S, et al
    Impact of HBsAg seroclearance on late recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection.
    J Hepatol. 2022 May 25. pii: S0168-8278(22)00329.
    PubMed     Abstract available


  139. DING WX, Ni HM, Waguri S, Komatsu M, et al
    Lack of Hepatic Autophagy Promotes Severity of Liver Injury but Not Steatosis.
    J Hepatol. 2022 May 25. pii: S0168-8278(22)00330.
    PubMed    


  140. CHU CM, Liaw YF
    Hepatocyte expression of hepatitis B surface and core antigens across phases of chronic hepatitis B infection.
    J Hepatol. 2022 May 20. pii: S0168-8278(22)00324.
    PubMed    


  141. HUSAIN A, Chiu YT, Oi-Lin Ng I
    EFNAs are functional predictors for overall survival of hepatocellular carcinoma patients.
    J Hepatol. 2022 May 20. pii: S0168-8278(22)00317.
    PubMed    


  142. MISHRA AK, Singh SP
    Seladelpar in patients with primary biliary cholangitis: Need a closer look!
    J Hepatol. 2022 May 17. pii: S0168-8278(22)00315.
    PubMed    


  143. GURI Y, Vosbeck J, Dickenmann M, Jetter A, et al
    Exacerbation of Familial Intrahepatic Cholestasis in Conjunction with COVID-19 Vaccination.
    J Hepatol. 2022 May 16. pii: S0168-8278(22)00313.
    PubMed    


  144. SEUNG KJ, Franke MF, Hewison C, Huerga H, et al
    Corrigendum to 'High prevalence of hepatitis C infection among multidrug-resistant tuberculosis patients' [J Hepatol 72 (2020) 1028-1029].
    J Hepatol. 2022 May 14. pii: S0168-8278(22)00247.
    PubMed    


  145. SUMAZIN P, Peters TL, Sarabia SF, Kim HR, et al
    Hepatoblastomas with carcinoma features represent a biological spectrum of aggressive neoplasms in children and young adults.
    J Hepatol. 2022 May 13. pii: S0168-8278(22)00275.
    PubMed     Abstract available


  146. YEUNG A, Palmateer NE, Dillon JF, McDonald SA, et al
    Corrigendum to 'Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs' [J Hepatol 76 (2022) 549-557].
    J Hepatol. 2022 May 9. pii: S0168-8278(22)00248.
    PubMed    


  147. WANG KC, Sun LY, Wang MD
    Methodological considerations regarding a gene signature to predict microvascular invasion in hepatocellular carcinoma.
    J Hepatol. 2022 May 5. pii: S0168-8278(22)00263.
    PubMed    


  148. SCHEINER B, Pinter M
    Reply to: "The CRAFITY score: a promising prognostic predictor for patients with hepatocellular carcinoma treated with tyrosine kinase inhibitor and immunotherapy combinations".
    J Hepatol. 2022 May 5. pii: S0168-8278(22)00266.
    PubMed    


  149. DE FRANCHIS R, Bosch J, Garcia-Tsao G, Reiberger T, et al
    Reply to: 'Management of portal hypertension in patients treated with atezolizumab and bevacizumab for hepatocellular carcinoma'.
    J Hepatol. 2022 May 5. pii: S0168-8278(22)00265.
    PubMed    


  150. SEMMLER G, Mandorfer M
    Substantiating evidence for HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease.
    J Hepatol. 2022 May 5. pii: S0168-8278(22)00267.
    PubMed    


  151. BHAGAT N, Verma N, Singh V
    HCC prediction post SVR in HCV patients: many tools yet limited generalizability!
    J Hepatol. 2022 May 5. pii: S0168-8278(22)00264.
    PubMed    


  152. WANG YZ
    Corrigendum to 'MAFLD supported by 95.45% participants of CSH is NOT representative' [J Hepatol 76 (2022) 481-482].
    J Hepatol. 2022 May 4. pii: S0168-8278(22)00246.
    PubMed    


  153. DONNELLY MC, Stableforth W, Krag A, Reuben A, et al
    The negative bidirectional interaction between climate change and the prevalence and care of liver disease: A joint BSG, BASL, EASL, and AASLD commentary.
    J Hepatol. 2022;76:995-1000.
    PubMed    


  154. REIG M, Bruix J
    Reply to: "Correspondence on the ".
    J Hepatol. 2022;76:1240-1241.
    PubMed    


  155. PETERMANN-ROCHA F, Gray SR, Forrest E, Welsh P, et al
    Associations of muscle mass and grip strength with severe NAFLD: A prospective study of 333,295 UK Biobank participants.
    J Hepatol. 2022;76:1021-1029.
    PubMed     Abstract available


  156. AHMAD J, Barnhart HX, Bonacini M, Ghabril M, et al
    Value of liver biopsy in the diagnosis of drug-induced liver injury.
    J Hepatol. 2022;76:1070-1078.
    PubMed     Abstract available


  157. LEE BP, Cullaro G, Vosooghi A, Yao F, et al
    Discordance in categorization of acute-on-chronic liver failure in the United Network for Organ Sharing database.
    J Hepatol. 2022;76:1122-1126.
    PubMed     Abstract available


  158. SCHEINER B, Balcar L, Nussbaumer RJ, Weinzierl J, et al
    Factor VIII/protein C ratio independently predicts liver-related events but does not indicate a hypercoagulable state in ACLD.
    J Hepatol. 2022;76:1090-1099.
    PubMed     Abstract available


  159. XU X, Lau WY, Yang T
    The updated BCLC staging system needs further refinement: A surgeon's perspective.
    J Hepatol. 2022;76:1239-1240.
    PubMed    


  160. MARJOT T, Ray DW, Tomlinson JW
    Is it time for chronopharmacology in NASH?
    J Hepatol. 2022;76:1215-1224.
    PubMed     Abstract available


  161. MAHMUD N, Chapin S, Goldberg DS, Reddy KR, et al
    Statin exposure is associated with reduced development of acute-on-chronic liver failure in a Veterans Affairs cohort.
    J Hepatol. 2022;76:1100-1108.
    PubMed     Abstract available


  162. BOURSIER J, Hagstrom H, Ekstedt M, Moreau C, et al
    Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events.
    J Hepatol. 2022;76:1013-1020.
    PubMed     Abstract available


  163. BERRY P, Kotha S
    Improving end of life care in liver disease.
    J Hepatol. 2022;76:1225-1226.
    PubMed    


  164. ELHENCE A, Shalimar
    Liver dysfunction in Barcelona Clinic Liver Cancer-2022 update: Clear as day or still in fog?
    J Hepatol. 2022;76:1236-1237.
    PubMed    


  165. GOVAERE O, Petersen SK, Martinez-Lopez N, Wouters J, et al
    Macrophage scavenger receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease.
    J Hepatol. 2022;76:1001-1012.
    PubMed     Abstract available


    April 2022
  166. TANTAI X, Yeo YH, Wang J, Ji F, et al
    Reply to: "Evaluating sarcopenia in cirrhosis patients: the role of muscle function".
    J Hepatol. 2022 Apr 30. pii: S0168-8278(22)00259.
    PubMed    


  167. FERNANDEZ J, Prado V, Valdivieso M, Trebicka J, et al
    Response to: Association of rectal colonization by mdros with new infection in cirrhosis.
    J Hepatol. 2022 Apr 30. pii: S0168-8278(22)00257.
    PubMed    


  168. LIU C, Zha Z, Zhou C, Chen Y, et al
    Erratum to 'Ribonuclease 7-driven activation of ROS1 is a potential therapeutic target in hepatocellular carcinoma' [J Hepatol 2021 (907-918)].
    J Hepatol. 2022 Apr 27. pii: S0168-8278(22)00240.
    PubMed    


  169. LABENZ C, Arslanow A, Nguyen-Tat M, Nagel M, et al
    Structured Early detection of Asymptomatic Liver Cirrhosis: Results of the population-based liver screening program SEAL.
    J Hepatol. 2022 Apr 23. pii: S0168-8278(22)00244.
    PubMed     Abstract available


  170. MAIWALL R, Kumar A, Pasupuleti SSR, Hidam AK, et al
    A randomized-controlled trial comparing 20% albumin to plasmalyte in patients with cirrhosis and sepsis-induced hypotension [ALPS trial].
    J Hepatol. 2022 Apr 20. pii: S0168-8278(22)00239.
    PubMed     Abstract available


  171. ZHANGYUAN G
    Is beta-catenin mutation in murine hepatocytes sufficient to induce liver tumorigenesis?
    J Hepatol. 2022 Apr 19. pii: S0168-8278(22)00242.
    PubMed    


  172. JIANG X, Fulte S, Deng F, Chen S, et al
    Lack of VMP1 Impairs Hepatic Lipoprotein Secretion and Promotes Nonalcoholic Steatohepatitis.
    J Hepatol. 2022 Apr 19. pii: S0168-8278(22)00245.
    PubMed     Abstract available


  173. ALKHOURI N, Herring R, Kabler H, Kayali Z, et al
    Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial.
    J Hepatol. 2022 Apr 16. pii: S0168-8278(22)00235.
    PubMed     Abstract available


  174. DE FRANCHIS R, Bosch J, Garcia-Tsao G, Reiberger T, et al
    Corrigendum to 'Baveno VII - Renewing consensus in portal hypertension' [J Hepatol (2022) 959-974].
    J Hepatol. 2022 Apr 14. pii: S0168-8278(22)00198.
    PubMed    


  175. CHUAH S, Lee J, Song Y, Kim HD, et al
    Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma.
    J Hepatol. 2022 Apr 14. pii: S0168-8278(22)00233.
    PubMed     Abstract available


  176. LI C, Ouyang W, Yang T
    The association of microvascular invasion with satellite nodule, tumor multiplicity, tumor encapsulation and resection margin of hepatocellular carcinoma.
    J Hepatol. 2022 Apr 10. pii: S0168-8278(22)00228.
    PubMed    


  177. CHAPIRO J
    Translating artificial intelligence from code to bedside: The road towards AI-driven predictive biomarkers for immunotherapy of hepatocellular carcinoma.
    J Hepatol. 2022 Apr 10. pii: S0168-8278(22)00227.
    PubMed    


  178. YANG H, Bae SH, Nam H, Lee HL, et al
    A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
    J Hepatol. 2022 Apr 7. pii: S0168-8278(22)00208.
    PubMed     Abstract available


  179. RUSSO FP, Vigano M, Stock P, Ferrarese A, et al
    HBV-positive and HIV-positive organs in transplantation: a clinical guide for the hepatologist.
    J Hepatol. 2022 Apr 7. pii: S0168-8278(22)00175.
    PubMed     Abstract available


  180. YANG T, Poenisch M, Khanal R, Hu Q, et al
    Corrigendum to 'Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model' [J Hepatol (2021) 1420-1433].
    J Hepatol. 2022 Apr 7. pii: S0168-8278(22)00197.
    PubMed    


  181. TSAY HC, Yuan Q, Balakrishnan A, Kaiser M, et al
    Corrigendum to: 'Hepatocyte-specific suppression of microRNA-221-3p mitigates liver fibrosis' [J Hepatol (2019) 722-734].
    J Hepatol. 2022 Apr 6. pii: S0168-8278(22)00196.
    PubMed    


  182. DEMIR M, Lang S, Hartmann P, Duan Y, et al
    The fecal mycobiome in non-alcoholic fatty liver disease.
    J Hepatol. 2022;76:788-799.
    PubMed     Abstract available


  183. MEHAL WZ, Schwabe RF
    A disease-promoting role of the intestinal mycobiome in non-alcoholic fatty liver disease.
    J Hepatol. 2022;76:765-767.
    PubMed    


  184. CHALASANI N, Bonkovsky HL, Stine JG, Gu J, et al
    Clinical characteristics of antiepileptic-induced liver injury in patients from the DILIN prospective study.
    J Hepatol. 2022;76:832-840.
    PubMed     Abstract available


  185. BYRNE CD, Newsome PN, Noureddin M
    Why are there no strategies for NAFLD?
    J Hepatol. 2022;76:763-764.
    PubMed    


  186. LAZARUS JV, Mark HE, Villota-Rivas M, Palayew A, et al
    The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?
    J Hepatol. 2022;76:771-780.
    PubMed     Abstract available


  187. FROMME M, Schneider CV, Trautwein C, Brunetti-Pierri N, et al
    Alpha-1 antitrypsin deficiency: A re-surfacing adult liver disorder.
    J Hepatol. 2022;76:946-958.
    PubMed     Abstract available


  188. NOUREDDIN M, Truong E, Gornbein JA, Saouaf R, et al
    MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis.
    J Hepatol. 2022;76:781-787.
    PubMed     Abstract available


  189. SCORLETTI E, Carr RM
    A new perspective on NAFLD: Focusing on lipid droplets.
    J Hepatol. 2022;76:934-945.
    PubMed     Abstract available


    March 2022
  190. BARSCH M, Salie H, Schlaak AE, Zhang Z, et al
    T cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma.
    J Hepatol. 2022 Mar 31. pii: S0168-8278(22)00180.
    PubMed     Abstract available


  191. WANG S, Wu Q, Chen T, Su R, et al
    Blocking CD47 promotes anti-tumor immunity through CD103+ dendritic cell-NK cell axis in murine hepatocellular carcinoma model.
    J Hepatol. 2022 Mar 31. pii: S0168-8278(22)00179.
    PubMed     Abstract available


  192. LI D, Yi C, Huang H, Li J, et al
    Hepatocyte specific depletion of Nnmt protects the mice from non-alcoholic steatohepatitis.
    J Hepatol. 2022 Mar 30. pii: S0168-8278(22)00191.
    PubMed    


  193. BOWLUS CL, Galambos MR, Aspinall RJ, Hirschfield GM, et al
    A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis.
    J Hepatol. 2022 Mar 30. pii: S0168-8278(22)00187.
    PubMed     Abstract available


  194. ZANETTO A, Campello E, Bulato C, Gavasso S, et al
    Increased platelet aggregation in patients with decompensated cirrhosis indicates higher risk of further decompensation and death.
    J Hepatol. 2022 Mar 29. pii: S0168-8278(22)00177.
    PubMed     Abstract available


  195. JALAN R, Rose CF
    Heretical thoughts into Hepatic Encephalopathy.
    J Hepatol. 2022 Mar 28. pii: S0168-8278(22)00183.
    PubMed     Abstract available


  196. BEAULANT A, Dia M, Pillot B, Chauvin MA, et al
    Endoplasmic reticulum-mitochondria miscommunication is an early and causal trigger of hepatic insulin resistance and steatosis.
    J Hepatol. 2022 Mar 28. pii: S0168-8278(22)00185.
    PubMed     Abstract available


  197. LIN P, Yang H
    EFNA3 is a prognostic biomarker for the overall survival of hepatocellular carcinoma patients.
    J Hepatol. 2022 Mar 28. pii: S0168-8278(22)00176.
    PubMed    


  198. TAPPER EB, Essien UR, Zhao Z, Ufere NN, et al
    Racial and ethnic disparities in rifaximin use and subspecialty referrals for patients with hepatic encephalopathy in the United States.
    J Hepatol. 2022 Mar 28. pii: S0168-8278(22)00116.
    PubMed     Abstract available


  199. MAGYAR CTJ, Beldi G, Banz V
    Impact of MELD 30-allocation policy on liver transplant outcomes in Italy: Considerations.
    J Hepatol. 2022 Mar 28. pii: S0168-8278(22)00186.
    PubMed    


  200. TANTAI X, Yeo YH, Wang J, Ji F, et al
    Reply to: "Gut liver muscle brain axis: a comprehensive viewpoint on prognosis in cirrhosis".
    J Hepatol. 2022 Mar 26. pii: S0168-8278(22)00182.
    PubMed    


  201. YANG Y, Ouyang J, Zhou Y, Zhou J, et al
    The CRAFITY score: a promising prognostic predictor for patients with hepatocellular carcinoma treated with tyrosine kinase inhibitor and immunotherapy combinations.
    J Hepatol. 2022 Mar 26. pii: S0168-8278(22)00188.
    PubMed    


  202. XIONG J, Tian Y
    Evaluating sarcopenia in cirrhosis patients: the role of muscle function.
    J Hepatol. 2022 Mar 26. pii: S0168-8278(22)00190.
    PubMed    


  203. TRIPODI A
    Cirrhosis. What are all those factor VIII and protein C for?
    J Hepatol. 2022 Mar 26. pii: S0168-8278(22)00189.
    PubMed    


  204. SCHWARZ C, Chromy D, Bangert C, Schwarz M, et al
    Immediate-type hypersensitivity reaction to bulevirtide and successful desensitization in a patient with HBV/HDV-associated compensated cirrhosis.
    J Hepatol. 2022 Mar 16. pii: S0168-8278(22)00172.
    PubMed    


  205. SUN R, Zhang Z, Bao R, Guo X, et al
    Loss of SIRT5 promotes bile acid-induced immunosuppressive microenvironment and hepatocarcinogenesis.
    J Hepatol. 2022 Mar 12. pii: S0168-8278(22)00139.
    PubMed     Abstract available


  206. WANG Q, Zhou H, Bu Q, Wei S, et al
    Role of XBP1 in regulating the progression of non-alcoholic steatohepatitis.
    J Hepatol. 2022 Mar 12. pii: S0168-8278(22)00140.
    PubMed     Abstract available


  207. NAKATSUKA T, Tateishi R, Nakagomi R, Minami T, et al
    Risk stratification of hepatocellular carcinoma after hepatitis C virus eradication in patients with compensated advanced chronic liver disease in Japan.
    J Hepatol. 2022 Mar 11. pii: S0168-8278(22)00138.
    PubMed    


  208. WHITFIELD JB, Schwantes-An TH, Darlay R, Aithal GP, et al
    Corrigendum to: 'A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers' [J Hepatol 2022 (76) 275-282].
    J Hepatol. 2022 Mar 11. pii: S0168-8278(22)00117.
    PubMed    


  209. TORGERSEN J, Taddei TH, Lo Re V 3rd
    Reply to: "Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with PI-based DAA?"
    J Hepatol. 2022 Mar 10. pii: S0168-8278(22)00132.
    PubMed    


  210. SINGH SP, Jindal A
    Association of rectal colonisation by MDROs with new infection in cirrhosis.
    J Hepatol. 2022 Mar 9. pii: S0168-8278(22)00135.
    PubMed    


  211. SUN X, Wu J, Liu L, Chen Y, et al
    Transcriptional switch of hepatocytes initiates macrophage recruitment and T cell suppression in endotoxemia.
    J Hepatol. 2022 Mar 8. pii: S0168-8278(22)00136.
    PubMed     Abstract available


  212. INNES H, Morling JR, Buch S, Hamill V, et al
    Performance of routine risk scores for predicting cirrhosis-related morbidity in the community.
    J Hepatol. 2022 Mar 7. pii: S0168-8278(22)00129.
    PubMed     Abstract available


  213. XU L, Yang Y, Wen Y, Jeong JM, et al
    Hepatic recruitment of eosinophils and their protective function during acute liver injury.
    J Hepatol. 2022 Mar 5. pii: S0168-8278(22)00131.
    PubMed     Abstract available


  214. LOESCH R, Caruso S, Paradis V, Godard C, et al
    Deleting the beta-catenin degradation domain in mouse hepatocytes drives hepatocellular carcinoma or hepatoblastoma-like tumor growth.
    J Hepatol. 2022 Mar 4. pii: S0168-8278(22)00130.
    PubMed     Abstract available



  215. EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis.
    J Hepatol. 2022 Mar 2. pii: S0168-8278(21)02033.
    PubMed     Abstract available


  216. SPELIOTES EK, George J
    Metabolic and genetic contributions to NAFLD: Really distinct and homogeneous?
    J Hepatol. 2022;76:498-500.
    PubMed    


  217. DING WX, Sancho-Bru P
    SOX9 acts downstream of YAP to decide liver cell fate and tumor types.
    J Hepatol. 2022;76:503-505.
    PubMed    


  218. MARTINEZ J, Hernandez-Gea V, Albillos A
    Reply to: "Potential novel approaches to prevent the risk of infection in patients with variceal bleeding".
    J Hepatol. 2022;76:752-753.
    PubMed    


  219. SHALTOUT I, Alkandari H, Fouad Y, Hamed AE, et al
    Arabic Association for the Study of Diabetes and Metabolism (AASD) endorsing the MAFLD definition of fatty liver disease.
    J Hepatol. 2022;76:739-740.
    PubMed    


  220. DEPRET F, Bouam S, Schwarzinger M, Mallet V, et al
    Reply to: "Focus on the decisions to forego life-sustaining therapies during ICU stay of patients with cirrhosis and COVID-19: A case control study from the prospective COVID-ICU database".
    J Hepatol. 2022;76:744-747.
    PubMed    


  221. EL-SHABRAWI M, Memon I, Attia D, El-Koofy NM, et al
    The International Society of Tropical Paediatrics (ISTP) endorses the redefinition of fatty liver disease.
    J Hepatol. 2022;76:738-739.
    PubMed    


  222. LIU D, Zhang Q, Bai P, Zhao J, et al
    Assessing causal relationships between COVID-19 and non-alcoholic fatty liver disease.
    J Hepatol. 2022;76:740-742.
    PubMed    


  223. WEBER ND, Martinez-Garcia J, Gonzalez-Aseguinolaza G
    Comment on "Synthetic human ABCB4 mRNA therapy rescues severe liver disease phenotype in a BALB/c.Abcb4(-/-) mouse model of PFIC3".
    J Hepatol. 2022;76:749-751.
    PubMed    


  224. ALABSAWY E, Shalimar, Jalan R
    Potential novel approaches to prevent the risk of infection in patients with variceal bleeding.
    J Hepatol. 2022;76:751-752.
    PubMed    



  225. Expression of concern: "The risk-benefit assessment of liver biopsy in times of non-invasive screening for liver fibrosis" by Ivana Ilic and Tamara Milovanovic [J Hepatol 73 (2020) 701-702].
    J Hepatol. 2022;76:758.
    PubMed    


  226. GUO B, Guo Y, Nima Q, Feng Y, et al
    Exposure to air pollution is associated with an increased risk of metabolic dysfunction-associated fatty liver disease.
    J Hepatol. 2022;76:518-525.
    PubMed     Abstract available


  227. REIG M, Forner A, Rimola J, Ferrer-Fabrega J, et al
    BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update.
    J Hepatol. 2022;76:681-693.
    PubMed     Abstract available


  228. KRONSTEN VT, Tranah TH, Pariante C, Shawcross DL, et al
    Gut-derived systemic inflammation as a driver of depression in chronic liver disease.
    J Hepatol. 2022;76:665-680.
    PubMed     Abstract available


  229. RINELLA ME, Dufour JF, Anstee QM, Goodman Z, et al
    Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study.
    J Hepatol. 2022;76:536-548.
    PubMed     Abstract available


  230. RATZIU V, Rinella ME, Neuschwander-Tetri BA, Lawitz E, et al
    EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study.
    J Hepatol. 2022;76:506-517.
    PubMed     Abstract available


  231. LUUKKONEN PK, Qadri S, Ahlholm N, Porthan K, et al
    Distinct contributions of metabolic dysfunction and genetic risk factors in the pathogenesis of non-alcoholic fatty liver disease.
    J Hepatol. 2022;76:526-535.
    PubMed     Abstract available


  232. YIP TC, Lee HW, Chan WK, Wong GL, et al
    Asian perspective on NAFLD-associated HCC.
    J Hepatol. 2022;76:726-734.
    PubMed     Abstract available


    February 2022
  233. HUSAIN A, Chiu YT, Sze KM, Ho DW, et al
    Ephrin-A3/EphA2 axis regulates cellular metabolic plasticity to enhance cancer stemness in hypoxic hepatocellular carcinoma.
    J Hepatol. 2022 Feb 25. pii: S0168-8278(22)00125.
    PubMed     Abstract available


  234. NINGARHARI M, Caruso S, Hirsch TZ, Bayard Q, et al
    Corrigendum to: 'Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target' [J Hepatol 2021 (74) 1155-1166].
    J Hepatol. 2022 Feb 24. pii: S0168-8278(22)00061.
    PubMed    


  235. WEI CY, Zhu MX, Zhang PF, Huang XY, et al
    PKCalpha/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma.
    J Hepatol. 2022 Feb 24. pii: S0168-8278(22)00126.
    PubMed     Abstract available


  236. MONTANARI NR, Ramirez R, Aggarwal A, van Buuren N, et al
    Multi-parametric analysis of human livers reveals variation in intrahepatic inflammation across phases of chronic hepatitis B infection.
    J Hepatol. 2022 Feb 23. pii: S0168-8278(22)00123.
    PubMed     Abstract available


  237. PATIDAR KR, Naved MA, Grama A, Adibuzzaman M, et al
    Acute Kidney Disease is Common and Associated with Poor Outcomes in Patients with Cirrhosis and Acute Kidney Injury.
    J Hepatol. 2022 Feb 22. pii: S0168-8278(22)00115.
    PubMed     Abstract available


  238. OLLIVIER-HOURMAND I, Allaire M, Cervoni JP
    Management of portal hypertension in patients treated with Atezolizumab and Bevacizumab for hepatocellular carcinoma.
    J Hepatol. 2022 Feb 16. pii: S0168-8278(22)00079.
    PubMed    


  239. SCHEINER B, Pinter M
    The CRAFITY score: A new guidepost for prognosis prediction in patients with hepatocellular carcinoma undergoing immunotherapy - authors' reply.
    J Hepatol. 2022 Feb 14. pii: S0168-8278(22)00073.
    PubMed    


  240. FONDEVILA MF, Fernandez U, Heras V, Parracho T, et al
    Inhibition of carnitine palmitoyl-transferase 1A in hepatic stellate cells protects against fibrosis.
    J Hepatol. 2022 Feb 12. pii: S0168-8278(22)00077.
    PubMed     Abstract available


  241. JEONG J, Tanaka M, Iwakiri Y
    Hepatic lymphatic vascular system in health and disease.
    J Hepatol. 2022 Feb 11. pii: S0168-8278(22)00071.
    PubMed     Abstract available


  242. MUELLER PP, Chen Q, Ayer T, Nemutlu G, et al
    Duration and cost-effectiveness of hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication.
    J Hepatol. 2022 Feb 11. pii: S0168-8278(22)00074.
    PubMed     Abstract available


  243. ZHOU SL, Zhou ZJ, Hu ZQ, Song CL, et al
    Corrigendum to 'Genomic sequencing identifies WNK2 as a driver in hepatocellular carcinoma and a risk factor for early recurrence' [J Hepatol 71 (2019) 1152-63].
    J Hepatol. 2022 Feb 9. pii: S0168-8278(22)00026.
    PubMed    


  244. ZINGONI A, Banales JM
    PIGR-enriched circulating vesicles contributes to hepatocellular carcinoma aggressiveness.
    J Hepatol. 2022 Feb 8. pii: S0168-8278(22)00070.
    PubMed    


  245. ZENG Q, Klein C, Caruso S, Maille P, et al
    Artificial intelligence predicts immune and inflammatory gene signatures directly from hepatocellular carcinoma histology.
    J Hepatol. 2022 Feb 7. pii: S0168-8278(22)00031.
    PubMed     Abstract available


  246. SINGAL AG, Zhang E, Narasimman M, Rich NE, et al
    HCC Surveillance Improves Early Detection, Curative Treatment Receipt, and Survival in Patients with Cirrhosis: A Systematic Review and Meta-Analysis.
    J Hepatol. 2022 Feb 6. pii: S0168-8278(22)00068.
    PubMed     Abstract available


  247. GHALLAB A, Hassan R, Hofmann U, Friebel A, et al
    Interruption of bile acid uptake by hepatocytes after acetaminophen overdose ameliorates hepatotoxicity.
    J Hepatol. 2022 Feb 4. pii: S0168-8278(22)00062.
    PubMed     Abstract available


  248. JACHS M, Scheiner B, Pinter M
    Letter to the editor: Immunotherapy for hepatocellular carcinoma in a patient with hepatitis B virus and hepatitis delta virus coinfection.
    J Hepatol. 2022 Feb 3. pii: S0168-8278(22)00030.
    PubMed    


  249. ENGELMANN C, Bruns T, Berg T
    Reply to: "G-CSF in acute-on-chronic liver failure - Art of 'patient selection' is paramount!"
    J Hepatol. 2022;76:473-475.
    PubMed    


  250. KIM D, Ahmed A
    Reply to: "NAFLD vs. MAFLD - It is not the name but the disease that decides the outcome in fatty liver".
    J Hepatol. 2022;76:477-478.
    PubMed    


  251. FOUAD YM, Mendez-Sanchez N, Zheng MH
    One not like the other: The weakness of the blood sugar-MAFLD analogy.
    J Hepatol. 2022;76:482-484.
    PubMed    


  252. DE A, Ahmad N, Mehta M, Singh P, et al
    NAFLD vs. MAFLD - It is not the name but the disease that decides the outcome in fatty liver.
    J Hepatol. 2022;76:475-477.
    PubMed    


  253. JINDAL A, Sarin SK
    G-CSF in acute-on-chronic liver failure - Art of 'patient selection' is paramount!
    J Hepatol. 2022;76:472-473.
    PubMed    


  254. WANG YZ
    MAFLD supported by 95.45% participants of CSH is NOT representative.
    J Hepatol. 2022;76:481-482.
    PubMed    


  255. BJORNSSON ES, Andrade RJ
    Long-term sequelae of drug-induced liver injury.
    J Hepatol. 2022;76:435-445.
    PubMed     Abstract available


  256. DANA J, Debray D, Beaufrere A, Hillaire S, et al
    Cystic fibrosis-related liver disease: Clinical presentations, diagnostic and monitoring approaches in the era of CFTR modulator therapies.
    J Hepatol. 2022;76:420-434.
    PubMed     Abstract available


  257. MALLET V, Parlati L, Martinino A, Scarano Pereira JP, et al
    Burden of liver disease progression in hospitalized patients with type 2 diabetes mellitus.
    J Hepatol. 2022;76:265-274.
    PubMed     Abstract available


  258. FOERSTER F, Gairing SJ, Muller L, Galle PR, et al
    NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options.
    J Hepatol. 2022;76:446-457.
    PubMed     Abstract available


    January 2022
  259. YANG M, Wu X, Hu J, Wang Y, et al
    COMMD10 inhibits HIF1alpha/CP loop to enhance ferroptosis and radiosensitivity by disrupting Cu-Fe balance in hepatocellular carcinoma.
    J Hepatol. 2022 Jan 28. pii: S0168-8278(22)00022.
    PubMed     Abstract available


  260. BRUNT EM, Clouston AD, Goodman Z, Guy C, et al
    Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD.
    J Hepatol. 2022 Jan 25. pii: S0168-8278(22)00024.
    PubMed     Abstract available


  261. RIDOLA L, Gioia S, Faccioli J, Riggio O, et al
    Gut liver muscle brain axis: a comprehensive viewpoint on prognosis in cirrhosis.
    J Hepatol. 2022 Jan 25. pii: S0168-8278(22)00016.
    PubMed    


  262. LIMON-MIRO AT, Jackson CD, Eslamparast T, Yamanaka-Okumura H, et al
    Predicted estimates of resting energy expenditure have limited clinical utility in patients with cirrhosis.
    J Hepatol. 2022 Jan 25. pii: S0168-8278(22)00018.
    PubMed     Abstract available


  263. PRADO V, Hernandez-Tejero M, Mucke MM, Marco F, et al
    Rectal colonization by resistant bacteria increases the risk of infection by the colonizing strain in critically ill patients with cirrhosis.
    J Hepatol. 2022 Jan 21. pii: S0168-8278(22)00013.
    PubMed     Abstract available


  264. BUONOMO E, Mei S, Guinn S, Leo I, et al
    Liver Stromal Cells Restrict Macrophage Maturation and Stromal IL-6 Limits the Differentiation of Cirrhosis-linked Macrophages.
    J Hepatol. 2022 Jan 21. pii: S0168-8278(22)00007.
    PubMed     Abstract available


  265. WONG YJ, Nguyen MH
    Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with PI-based DAA?
    J Hepatol. 2022 Jan 21. pii: S0168-8278(22)00008.
    PubMed    


  266. ZHOU HF, Yang W, Zhou WZ
    The CRAFITY score: A new guidepost for prognosis prediction in patients with hepatocellular carcinoma undergoing immunotherapy.
    J Hepatol. 2022 Jan 18. pii: S0168-8278(22)00004.
    PubMed    


  267. D'AMICO G, Bernardi M, Angeli P
    Corrigendum to 'Towards a new definition of decompensated cirrhosis' [J Hepatol 76 (2022) 202-207].
    J Hepatol. 2022 Jan 5. pii: S0168-8278(21)02300.
    PubMed    


  268. CRAMER T, Vaupel P
    Severe hypoxia is a typical characteristic of human hepatocellular carcinoma: Scientific fact or fallacy?
    J Hepatol. 2022 Jan 3. pii: S0168-8278(21)02305.
    PubMed     Abstract available


  269. JAGADISAN B, Dhawan A
    Emergencies in Pediatric hepatology.
    J Hepatol. 2022 Jan 3. pii: S0168-8278(21)02304.
    PubMed     Abstract available


  270. MALLET V, Schwarzinger M
    Reply to: "Association of chronic liver disease with the prognosis of COVID-19 patients".
    J Hepatol. 2022;76:229-230.
    PubMed    


  271. LONG J, Sang X, Zhao H
    Association of chronic liver disease with the prognosis of COVID-19 patients.
    J Hepatol. 2022;76:228-229.
    PubMed    


  272. SHROFF H, Satapathy SK, Crawford JM, Todd NJ, et al
    Liver injury following SARS-CoV-2 vaccination: A multicenter case series.
    J Hepatol. 2022;76:211-214.
    PubMed    


  273. SCHUPPAN D, Myneni S, Surabattula R
    Liquid biomarkers for fibrotic NASH - progress in a complex field.
    J Hepatol. 2022;76:5-7.
    PubMed    



  274. Reply to: Correspondence on "EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update".
    J Hepatol. 2022;76:251-252.
    PubMed    


  275. THULUVATH PJ, Li F
    Reply to: "Universal definition and prognostication in acute-on- chronic liver failure - an unmet need!"
    J Hepatol. 2022;76:242-243.
    PubMed    


  276. TURON F, Lisman T, Carlos-Garcia-Pagan J
    Reply to: Correspondence on "Predicting portal thrombosis in cirrosis: A prospective study of clinical, ultrasonographic and hemostatic factors".
    J Hepatol. 2022;76:227-228.
    PubMed    


  277. LI B, He Q, Lu G, Hong C, et al
    Minor role of hemostatic alternation in portal vein thrombosis pathogenesis revealed by global measurement.
    J Hepatol. 2022;76:225-227.
    PubMed    


  278. VAN KLEEF LA, Sonneveld MJ, de Man RA, de Knegt RJ, et al
    Poor performance of FIB-4 in elderly individuals at risk for chronic liver disease - implications for the clinical utility of the EASL NIT guideline.
    J Hepatol. 2022;76:245-246.
    PubMed    


  279. VERMA N, Mehtani R, Duseja A
    Universal definition and prognostication in acute-on-chronic liver failure - an unmet need!
    J Hepatol. 2022;76:241-242.
    PubMed    


  280. LIU Y, Liu C, Li J, Kim TH, et al
    Risk stratification of decompensation using liver stiffness and platelet counts in compensated advanced chronic liver disease (CHESS2102).
    J Hepatol. 2022;76:248-250.
    PubMed    


  281. COREY KE, Pitts R, Lai M, Loureiro J, et al
    ADAMTSL2 protein and a soluble biomarker signature identify at-risk non-alcoholic steatohepatitis and fibrosis in adults with NAFLD.
    J Hepatol. 2022;76:25-33.
    PubMed     Abstract available


  282. DA SILVA LIMA N, Fondevila MF, Novoa E, Buque X, et al
    Inhibition of ATG3 ameliorates liver steatosis by increasing mitochondrial function.
    J Hepatol. 2022;76:11-24.
    PubMed     Abstract available


  283. VOGEL A, Saborowski A
    Medical therapy of HCC.
    J Hepatol. 2022;76:208-210.
    PubMed    


  284. LOOSEN SH, Kostev K, Keitel V, Tacke F, et al
    An elevated FIB-4 score predicts liver cancer development: A longitudinal analysis from 29,999 patients with NAFLD.
    J Hepatol. 2022;76:247-248.
    PubMed    


  285. SINGAL AG, El-Serag HB
    Rational HCC screening approaches for patients with NAFLD.
    J Hepatol. 2022;76:195-201.
    PubMed     Abstract available


  286. BJORNSSON HK, Gudbjornsson B, Bjornsson ES
    Infliximab-induced liver injury: Clinical phenotypes, autoimmunity and the role of corticosteroid treatment.
    J Hepatol. 2022;76:86-92.
    PubMed     Abstract available


  287. SEKIBA K, Otsuka M, Funato K, Miyakawa Y, et al
    HBx-induced degradation of Smc5/6 complex impairs homologous recombination-mediated repair of damaged DNA.
    J Hepatol. 2022;76:53-62.
    PubMed     Abstract available


  288. ZHANG IW, Curto A, Lopez-Vicario C, Casulleras M, et al
    Mitochondrial dysfunction governs immunometabolism in leukocytes of patients with acute-on-chronic liver failure.
    J Hepatol. 2022;76:93-106.
    PubMed     Abstract available


  289. GHELFI J, Brusset B, Thony F, Decaens T, et al
    Successful management of refractory ascites in non-TIPSable patients using percutaneous thoracic duct stenting.
    J Hepatol. 2022;76:216-218.
    PubMed    


    December 2021
  290. SCHEINER B, Pinter M
    Letter to the Editor: Prognostic prediction for patients with hepatocellular carcinoma receiving immunotherapy: Are we there yet? - authors' reply.
    J Hepatol. 2021 Dec 31. pii: S0168-8278(21)02302.
    PubMed    


  291. DE FRANCHIS R, Bosch J, Garcia-Tsao G, Reiberger T, et al
    Baveno VII - Renewing consensus in portal hypertension.
    J Hepatol. 2021 Dec 30. pii: S0168-8278(21)02299.
    PubMed     Abstract available


  292. BELLI LS, Perricone G, Jalan R
    Reply to: Sarcopenia should be evaluated in patients with acute-on-chronic liver failure and candidates to liver transplantation. Reply letter.
    J Hepatol. 2021 Dec 28. pii: S0168-8278(21)02293.
    PubMed    


  293. WANG H, Zhang S, Zhang Y, Jia J, et al
    Corrigendum to 'TAZ is indispensable for c-MYC-induced hepatocarcinogenesis' [J Hepatol (2022) 123-134].
    J Hepatol. 2021 Dec 26. pii: S0168-8278(21)02248.
    PubMed    


  294. GARRIDO A, Kim E, Teijeiro A, Sanchez PS, et al
    Histone acetylation of bile acid transporter genes plays a critical role in cirrhosis.
    J Hepatol. 2021 Dec 24. pii: S0168-8278(21)02294.
    PubMed     Abstract available


  295. SOUNDARARAJAN R, Gupta P
    Reply to "Abbreviated MRI to screen for HCC in patients with cirrhosis. A step forward but a long road ahead".
    J Hepatol. 2021 Dec 23. pii: S0168-8278(21)02292.
    PubMed    


  296. BEAUMONT E, Larochette V, Preisser L, Miot C, et al
    IL-26 inhibits hepatitis C virus replication in hepatocytes.
    J Hepatol. 2021 Dec 21. pii: S0168-8278(21)02253.
    PubMed     Abstract available


  297. TEY SK, Wong SWK, Tung Chan JY, Mao X, et al
    Patient pIgR-enriched extracellular vesicles drive cancer stemness, tumorigenesis and metastasis in hepatocellular carcinoma.
    J Hepatol. 2021 Dec 16. pii: S0168-8278(21)02245.
    PubMed     Abstract available


  298. WANG X, Zeldin S, Shi H, Zhu C, et al
    TAZ-induced Cybb contributes to liver tumor formation in non-alcoholic steatohepatitis.
    J Hepatol. 2021 Dec 10. pii: S0168-8278(21)02242.
    PubMed     Abstract available


  299. CHENG AL, Qin S, Ikeda M, Galle PR, et al
    Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.
    J Hepatol. 2021 Dec 10. pii: S0168-8278(21)02241.
    PubMed     Abstract available


  300. CORDELL HJ, Fryett JJ, Ueno K, Darlay R, et al
    Corrigendum to 'An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs' [J Hepatol 2021;75(3):572-581].
    J Hepatol. 2021 Dec 9. pii: S0168-8278(21)02219.
    PubMed    


  301. KASSIANIDES C, Dusheiko G, Di Bisceglie A, Hoofnagle JH, et al
    Michael Charles Kew - Frontrunner in Hepatology.
    J Hepatol. 2021 Dec 6. pii: S0168-8278(21)02224.
    PubMed    


  302. KADONO K, Kageyama S, Nakamura K, Hirao H, et al
    Myeloid ikaros-SIRT1 signaling axis regulates hepatic inflammation and pyroptosis in ischemia-stressed mouse and human liver.
    J Hepatol. 2021 Dec 3. pii: S0168-8278(21)02235.
    PubMed     Abstract available


  303. NACHIT M, Kwanten WJ, Francque S
    Reply to: "Intermuscular abdominal fat fraction and metabolic dysfunction-associated fatty liver disease: Does the link already exist in childhood?"
    J Hepatol. 2021;75:1513-1514.
    PubMed    


  304. LUEDDE T, Baumann U, Keitel V
    Reply to: "Multiple investigations for a very common disorder: Finding the right balance in NAFLD".
    J Hepatol. 2021;75:1502-1503.
    PubMed    


  305. WONG VW, Lazarus JV
    Prognosis of MAFLD vs. NAFLD and implications for a nomenclature change.
    J Hepatol. 2021;75:1267-1270.
    PubMed    


  306. POHL J, Gebauer B, Gebert P, Tacke F, et al
    Predicting survival after TIPS: Child Pugh score is not inferior to MELD and FIPS score - back to basics?
    J Hepatol. 2021;75:1505-1506.
    PubMed    


  307. MATTHEWS C, Cross TJS
    Before we can find an evidence base for HCC surveillance, we need to define our target demographic.
    J Hepatol. 2021;75:1494-1495.
    PubMed    


  308. KOTHA S, Berry P
    Multiple investigations for a very common disorder: Finding the right balance in NAFLD.
    J Hepatol. 2021;75:1501-1502.
    PubMed    


  309. CADENAS-SANCHEZ C, Idoate F, Villanueva A, Cabeza R, et al
    Intermuscular abdominal fat fraction and metabolic dysfunction-associated fatty liver disease: Does the link already exist in childhood?
    J Hepatol. 2021;75:1511-1513.
    PubMed    


  310. NIELSEN MJ, Leeming DJ, Goodman Z, Friedman S, et al
    Comparison of ADAPT, FIB-4 and APRI as non-invasive predictors of liver fibrosis and NASH within the CENTAUR screening population.
    J Hepatol. 2021;75:1292-1300.
    PubMed     Abstract available


  311. IOANNOU GN
    Epidemiology and risk-stratification of NAFLD-associated HCC.
    J Hepatol. 2021;75:1476-1484.
    PubMed     Abstract available


  312. YANG T, Poenisch M, Khanal R, Hu Q, et al
    Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model.
    J Hepatol. 2021;75:1420-1433.
    PubMed     Abstract available


  313. HSU CL, Duan Y, Fouts DE, Schnabl B, et al
    Intestinal virome and therapeutic potential of bacteriophages in liver disease.
    J Hepatol. 2021;75:1465-1475.
    PubMed     Abstract available


  314. KIM D, Konyn P, Sandhu KK, Dennis BB, et al
    Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States.
    J Hepatol. 2021;75:1284-1291.
    PubMed     Abstract available


  315. ENGELMANN C, Herber A, Franke A, Bruns T, et al
    Granulocyte-colony stimulating factor (G-CSF) to treat acute-on-chronic liver failure: A multicenter randomized trial (GRAFT study).
    J Hepatol. 2021;75:1346-1354.
    PubMed     Abstract available


  316. GADALETA RM, Moschetta A
    Dark and bright side of targeting fibroblast growth factor receptor 4 in the liver.
    J Hepatol. 2021;75:1440-1451.
    PubMed     Abstract available


  317. D'AMICO G, Maruzzelli L, Airoldi A, Petridis I, et al
    Performance of the model for end-stage liver disease score for mortality prediction and the potential role of etiology.
    J Hepatol. 2021;75:1355-1366.
    PubMed     Abstract available


    November 2021
  318. CABIBBO G, Singal AG
    The quest for precision oncology with immune checkpoint inhibitors and hepatocellular carcinoma.
    J Hepatol. 2021 Nov 26. pii: S0168-8278(21)02226.
    PubMed    


  319. LIU Y, Zhuo S, Zhou Y, Ma L, et al
    Yap-Sox9 signaling determines hepatocyte plasticity and lineage-specific hepatocarcinogenesis.
    J Hepatol. 2021 Nov 15. pii: S0168-8278(21)02182.
    PubMed     Abstract available


  320. D'AVOLA D, Granito A, de la Torre-Alaez M, Piscaglia F, et al
    The importance of liver functional reserve in the non-surgical treatment of Hepatocellular Carcinoma.
    J Hepatol. 2021 Nov 15. pii: S0168-8278(21)02185.
    PubMed     Abstract available


  321. SABOO K, Petrakov NV, Shamsaddini A, Fagan A, et al
    Stool microbiota are superior to saliva in distinguishing cirrhosis and hepatic encephalopathy using machine learning.
    J Hepatol. 2021 Nov 15. pii: S0168-8278(21)02183.
    PubMed     Abstract available


  322. DING GY, Ma JQ, Yun JP, Chen X, et al
    Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma.
    J Hepatol. 2021 Nov 15. pii: S0168-8278(21)02178.
    PubMed     Abstract available


  323. TANTAI X, Liu Y, Yeo YH, Praktiknjo M, et al
    Effect of sarcopenia on survival in patients with cirrhosis: A systematic review and meta-analysis.
    J Hepatol. 2021 Nov 13. pii: S0168-8278(21)02174.
    PubMed     Abstract available


  324. HUO TI, Liao JI, Ho SY
    Prognostic prediction for patients with hepatocellular carcinoma receiving immunotherapy: Are we there yet?
    J Hepatol. 2021 Nov 12. pii: S0168-8278(21)02176.
    PubMed    


  325. XU X, Nan Y
    Reply to: Correspondence on "The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease".
    J Hepatol. 2021 Nov 11. pii: S0168-8278(21)02170.
    PubMed    


  326. RAVAIOLI M, Lai Q, Sessa M, Ghinolfi D, et al
    Impact of MELD 30-allocation policy on liver transplant outcomes in Italy.
    J Hepatol. 2021 Nov 10. pii: S0168-8278(21)02166.
    PubMed     Abstract available


  327. PAVLIDES M, Francis S, Barnes E
    Abbreviated MRI to screen for HCC in patients with cirrhosis. A step forward but a long road ahead.
    J Hepatol. 2021 Nov 8. pii: S0168-8278(21)02169.
    PubMed    


  328. COLOMBO M, Barouki R
    Expanding the liver exposome: should hepatologists care about air pollution?
    J Hepatol. 2021 Nov 5. pii: S0168-8278(21)02165.
    PubMed    


  329. SANGRO B, Bruix J, Chan SL, Galle PR, et al
    Immunotherapy for patients with hepatocellular carcinoma and chronic viral infections.
    J Hepatol. 2021 Nov 1. pii: S0168-8278(21)02162.
    PubMed    


  330. HAN Y, Black S, Gong Z, Chen Z, et al
    Membrane-delimited signaling and cytosolic action of MG53 preserve hepatocyte integrity during drug-induced liver injury.
    J Hepatol. 2021 Nov 1. pii: S0168-8278(21)02154.
    PubMed     Abstract available


  331. PAPATHEODORIDI M, Pinzani M, Tsochatzis E
    Reply to: "Baveno VI elastography criteria for ruling in cACLD works well in patients with MAFLD" and "Transient elastography in chronic liver disease: Beware of the cut-offs!"
    J Hepatol. 2021;75:1247.
    PubMed    


  332. GUPTA P, Sharma V, Kalra N
    Reply to: "Risk factors and screening intervals are crucial for evaluating the cost effectiveness of abbreviated MRI in HCC screening".
    J Hepatol. 2021;75:1259-1260.
    PubMed    


  333. VILLANUEVA C, Bosch J
    Reply to: "First things first! Can bacterial infections be considered as decompensating events per se?"
    J Hepatol. 2021;75:1242-1243.
    PubMed    


  334. KUTAIBA N, Ardalan Z
    Risk factors and screening intervals are crucial for evaluating the cost effectiveness of abbreviated MRI in HCC screening.
    J Hepatol. 2021;75:1258-1259.
    PubMed    


  335. JI Y, Li J, He Q, Zhou L, et al
    Baveno VI elastography criteria for ruling in cACLD works well in patients with MAFLD.
    J Hepatol. 2021;75:1243-1245.
    PubMed    


  336. CRISTOFERI L, Nardi A, Carbone M
    Transient elastography in chronic liver disease: Beware of the cut-offs!
    J Hepatol. 2021;75:1245-1246.
    PubMed    


  337. REICHERT MC, Ripoll C
    First things first! Can bacterial infections be considered as decompensating events per se?
    J Hepatol. 2021;75:1241-1242.
    PubMed    


  338. LANGE NF, Radu P, Dufour JF
    Prevention of NAFLD-associated HCC: Role of lifestyle and chemoprevention.
    J Hepatol. 2021;75:1217-1227.
    PubMed     Abstract available


  339. HAGSTROM H, Simon TG, Roelstraete B, Stephansson O, et al
    Maternal obesity increases the risk and severity of NAFLD in offspring.
    J Hepatol. 2021;75:1042-1048.
    PubMed     Abstract available


  340. RUIZ-BLAZQUEZ P, Pistorio V, Fernandez-Fernandez M, Moles A, et al
    The multifaceted role of cathepsins in liver disease.
    J Hepatol. 2021;75:1192-1202.
    PubMed     Abstract available


  341. SIMON TG, Roelstraete B, Hartjes K, Shah U, et al
    Non-alcoholic fatty liver disease in children and young adults is associated with increased long-term mortality.
    J Hepatol. 2021;75:1034-1041.
    PubMed     Abstract available


  342. WANG Q, Liang N, Yang T, Li Y, et al
    DNMT1-mediated methylation of BEX1 regulates stemness and tumorigenicity in liver cancer.
    J Hepatol. 2021;75:1142-1153.
    PubMed     Abstract available


  343. JALAN R, Gustot T, Fernandez J, Bernal W, et al
    'Equity' and 'Justice' for patients with acute-on chronic liver failure: A call to action.
    J Hepatol. 2021;75:1228-1235.
    PubMed     Abstract available


  344. FERRER-FABREGA J, Sampson-Davila J, Forner A, Sapena V, et al
    Limited tumour progression beyond Milan criteria while on the waiting list does not result in unacceptable impairment of survival.
    J Hepatol. 2021;75:1154-1163.
    PubMed     Abstract available


  345. RASMUSSEN DN, Thiele M, Johansen S, Kjaergaard M, et al
    Prognostic performance of 7 biomarkers compared to liver biopsy in early alcohol-related liver disease.
    J Hepatol. 2021;75:1017-1025.
    PubMed     Abstract available


  346. LI F, Thuluvath PJ
    EASL-CLIF criteria outperform NACSELD criteria for diagnosis and prognostication in ACLF.
    J Hepatol. 2021;75:1096-1103.
    PubMed     Abstract available


    October 2021
  347. CHAO X, Wang S, Fulte S, Ma X, et al
    Hepatocytic p62 suppresses ductular reaction and tumorigenesis in mouse livers with mTORC1 activation and defective autophagy.
    J Hepatol. 2021 Oct 25. pii: S0168-8278(21)02151.
    PubMed     Abstract available


  348. LOGLIO A, Ferenci P, Uceda Renteria SC, Tham CYL, et al
    Safety and effectiveness of up to 3 years' bulevirtide monotherapy in patients with HDV-related cirrhosis.
    J Hepatol. 2021 Oct 23. pii: S0168-8278(21)02119.
    PubMed     Abstract available


  349. LAN T, Hu Y, Hu F, Li H, et al
    Hepatocyte glutathione S-transferase mu 2 prevents non-alcoholic steatohepatitis by suppressing ASK1 signaling.
    J Hepatol. 2021 Oct 14. pii: S0168-8278(21)02105.
    PubMed     Abstract available


  350. WHITFIELD JB, Schwantes-An TH, Darlay R, Aithal GP, et al
    A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers.
    J Hepatol. 2021 Oct 13. pii: S0168-8278(21)02111.
    PubMed     Abstract available


  351. QING J, Ren Y, Zhang Y, Yan M, et al
    Dopamine receptor D2 antagonization normalizes profibrotic macrophage-endothelial crosstalk in non-alcoholic steatohepatitis.
    J Hepatol. 2021 Oct 11. pii: S0168-8278(21)02097.
    PubMed     Abstract available


  352. SCHEINER B, Pomej K, Kirstein MM, Hucke F, et al
    Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score.
    J Hepatol. 2021 Oct 11. pii: S0168-8278(21)02100.
    PubMed     Abstract available


  353. SEN P, Qadri S, Luukkonen PK, Ragnarsdottir O, et al
    Exposure to environmental contaminants is associated with altered hepatic lipid metabolism in non-alcoholic fatty liver disease.
    J Hepatol. 2021 Oct 7. pii: S0168-8278(21)02104.
    PubMed     Abstract available


  354. PINYOL R, Torrecilla S, Wang H, Montironi C, et al
    Corrigendum to 'Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis' [J Hepatol 75 (2021) 865-878].
    J Hepatol. 2021 Oct 6. pii: S0168-8278(21)02044.
    PubMed    


  355. BEAUFRERE A, Caruso S, Calderaro J, Pote N, et al
    Gene expression signature as a surrogate marker of microvascular invasion on routine hepatocellular carcinoma biopsies.
    J Hepatol. 2021 Oct 5. pii: S0168-8278(21)02099.
    PubMed     Abstract available


  356. KIM HY, Lampertico P, Nam JY, Lee HC, et al
    An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B.
    J Hepatol. 2021 Oct 1. pii: S0168-8278(21)02087.
    PubMed     Abstract available


  357. BAFFY G, Bosch J
    Overlooked subclinical portal hypertension in non-cirrhotic NAFLD: Is it real and how to measure it?
    J Hepatol. 2021 Oct 1. pii: S0168-8278(21)02090.
    PubMed     Abstract available


  358. WONG F, Piano S, Angeli P
    Reply to: Correspondence on "Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure".
    J Hepatol. 2021;75:1010-1012.
    PubMed    


  359. FENG MW, Hanley KL, Feng GS
    Androgen receptor, neovascularization and liver cancer metastasis.
    J Hepatol. 2021;75:768-769.
    PubMed    


  360. LIN S, Agarwal B, Kumar R, Jalan R, et al
    Defining the prognosis of critically ill patients with alcohol-related liver disease.
    J Hepatol. 2021;75:986-987.
    PubMed    


  361. FISCHER P, Stefanescu H, Hategan R, Procopet B, et al
    Bacterial infection-related acute-on-chronic liver failure: The standpoint matters!
    J Hepatol. 2021;75:1009-1010.
    PubMed    


  362. FERNANDEZ-CHECA JC, Bagnaninchi P, Ye H, Sancho-Bru P, et al
    Advanced preclinical models for evaluation of drug-induced liver injury - consensus statement by the European Drug-Induced Liver Injury Network [PRO-EURO-DILI-NET].
    J Hepatol. 2021;75:935-959.
    PubMed     Abstract available


  363. CHEN X, Chen S, Pang J, Tang Y, et al
    Are the different MAFLD subtypes based on the inclusion criteria correlated with all-cause mortality?
    J Hepatol. 2021;75:987-989.
    PubMed    


  364. LACKNER C, Stauber RE, Davies S, Denk H, et al
    Development and prognostic relevance of a histologic grading and staging system for alcohol-related liver disease.
    J Hepatol. 2021;75:810-819.
    PubMed     Abstract available


  365. YOUNES R, Caviglia GP, Govaere O, Rosso C, et al
    Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease.
    J Hepatol. 2021;75:786-794.
    PubMed     Abstract available


  366. GOLABI P, Paik JM, AlQahtani S, Younossi Y, et al
    Burden of non-alcoholic fatty liver disease in Asia, the Middle East and North Africa: Data from Global Burden of Disease 2009-2019.
    J Hepatol. 2021;75:795-809.
    PubMed     Abstract available


  367. SELVARAJ EA, Mozes FE, Jayaswal ANA, Zafarmand MH, et al
    Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis.
    J Hepatol. 2021;75:770-785.
    PubMed     Abstract available


    September 2021
  368. GIABICANI M, Le Menestrel A, Roux O, Rautou PE, et al
    Focus on the decisions to forego life-sustaining therapies during ICU stay of patients with cirrhosis and COVID-19: a case control study from the prospective COVID-ICU database.
    J Hepatol. 2021 Sep 30. pii: S0168-8278(21)02080.
    PubMed    


  369. HSIEH J, Molusky MM, McCabe KM, Fotakis P, et al
    TTC39B destabilizes retinoblastoma protein promoting hepatic lipogenesis in a sex-specific fashion.
    J Hepatol. 2021 Sep 30. pii: S0168-8278(21)02083.
    PubMed     Abstract available


  370. GRONEBERG M, Hoenow S, Marggraff C, Fehling H, et al
    HIF-1alpha modulates sex-specific Th17/Treg responses during hepatic amoebiasis.
    J Hepatol. 2021 Sep 29. pii: S0168-8278(21)02082.
    PubMed     Abstract available


  371. D'AMBROSIO R, Degasperi E, Anolli MP, Fanetti I, et al
    Incidence of liver and non-liver-related outcomes in patients with HCV-cirrhosis after SVR.
    J Hepatol. 2021 Sep 27. pii: S0168-8278(21)02043.
    PubMed     Abstract available


  372. CHOI WM, Yip TC, Lim YS, Wong GL, et al
    Methodological Challenges in Meta-Analysis to Assess the Risk of Hepatocellular Carcinoma Across Chronic Hepatitis B Treatments.
    J Hepatol. 2021 Sep 27. pii: S0168-8278(21)02079.
    PubMed     Abstract available


  373. PATEL V, Lee S, McPhail M, Da Silva K, et al
    Rifaximin reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial.
    J Hepatol. 2021 Sep 24. pii: S0168-8278(21)02040.
    PubMed     Abstract available


  374. KIM HS, Yu X, Kramer J, Thrift AP, et al
    Comparative performance of risk prediction models for hepatitis B-related hepatocellular carcinoma in the United States.
    J Hepatol. 2021 Sep 23. pii: S0168-8278(21)02039.
    PubMed     Abstract available


  375. ARTRU F, le Goffic C, Pageaux GP, Saliba F, et al
    Sarcopenia should be evaluated in patients with acute-on-chronic liver failure and candidates to liver transplantation.
    J Hepatol. 2021 Sep 15. pii: S0168-8278(21)02034.
    PubMed    


  376. JUANOLA A, Graupera I, Elia C, Piano S, et al
    Urinary L-FABP is a promising prognostic biomarker of ACLF and mortality in patients with decompensated cirrhosis.
    J Hepatol. 2021 Sep 13. pii: S0168-8278(21)02029.
    PubMed     Abstract available


  377. CHEN Q, Wang H, Li Z, Li F, et al
    Circular RNA ACTN4 promotes intrahepatic cholangiocarcinoma progression by recruiting YBX1 to initiate FZD7 transcription.
    J Hepatol. 2021 Sep 9. pii: S0168-8278(21)02025.
    PubMed     Abstract available


  378. DAI CY, Yeh ML, Yu ML
    An EASL position paper for systemic treatment of hepatocellular carcinoma: Go forward courageously.
    J Hepatol. 2021 Sep 4. pii: S0168-8278(21)02021.
    PubMed    


  379. VUPPALANCHI R, Caldwell SH, Pyrsopoulos N, deLemos AS, et al
    Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis.
    J Hepatol. 2021 Sep 3. pii: S0168-8278(21)02023.
    PubMed     Abstract available


  380. DING ZY, Li GX, Shu C, Yin P, et al
    Reply to: Comments on "Association of liver abnormalities with in-hospital mortality in patients with COVID-19".
    J Hepatol. 2021;75:742-744.
    PubMed    


  381. LUO MS, Huang GJ
    Letter regarding "Association of liver abnormalities with in-hospital mortality in patients with COVID-19".
    J Hepatol. 2021;75:737-739.
    PubMed    


  382. SINGH A, Premkumar M, Singh V
    Liver injury in COVID-19 - The culprit may not be COVID-19!
    J Hepatol. 2021;75:739-740.
    PubMed    


  383. MCCONNELL MJ, Kawaguchi N, Kondo R, Sonzogni A, et al
    Liver injury in COVID-19 and IL-6 trans-signaling-induced endotheliopathy.
    J Hepatol. 2021;75:647-658.
    PubMed     Abstract available


  384. WANG Q, Bai W, Han G
    Freiburg index of post-TIPS survival: The first score for individual prediction and a complementary tool for risk stratification.
    J Hepatol. 2021;75:747-749.
    PubMed    


  385. BETTINGER D, Thimme R, Schultheiss M
    Reply to: Correspondence on "Refining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival".
    J Hepatol. 2021;75:749-750.
    PubMed    


  386. PAPATHEODORIDI M, Pinzani M, Tsochatzis E
    Reply to: "Do we need to re-define the Baveno VI elastography criteria for compensated advanced chronic liver disease (cACLD)?"
    J Hepatol. 2021;75:752-753.
    PubMed    


  387. PARK H, Yoon EL, Cho S, Nah EH, et al
    Do we need a new cut-off for FIB-4 in the metabolic dysfunction-associated fatty liver disease era?
    J Hepatol. 2021;75:725-726.
    PubMed    


  388. MA L, Craig AJ, Heinrich S
    Hypoxia is a key regulator in liver cancer progression.
    J Hepatol. 2021;75:736-737.
    PubMed    


  389. KRAGLUND F, Gantzel RH, Jepsen P, Aagaard NK, et al
    External validation of the Freiburg index of post-TIPS survival.
    J Hepatol. 2021;75:746-747.
    PubMed    


  390. GENESCA J, Abraldes JG, Bosch J
    Do we need to re-define the Baveno VI elastography criteria for compensated advanced chronic liver disease (cACLD)?
    J Hepatol. 2021;75:750-752.
    PubMed    



  391. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update.
    J Hepatol. 2021;75:659-689.
    PubMed     Abstract available


  392. YOO T, Joo SK, Kim HJ, Kim HY, et al
    Disease-specific eQTL screening reveals an anti-fibrotic effect of AGXT2 in non-alcoholic fatty liver disease.
    J Hepatol. 2021;75:514-523.
    PubMed     Abstract available


  393. CORRADINI E, Buzzetti E, Dongiovanni P, Scarlini S, et al
    Ceruloplasmin gene variants are associated with hyperferritinemia and increased liver iron in patients with NAFLD.
    J Hepatol. 2021;75:506-513.
    PubMed     Abstract available


    August 2021
  394. WANG H, Zhang S, Zhang Y, Jia J, et al
    TAZ is indispensable for c-MYC-induced hepatocarcinogenesis.
    J Hepatol. 2021 Aug 28. pii: S0168-8278(21)02016.
    PubMed     Abstract available


  395. DAI CY, Chuang WL, Yu ML
    A prospective study in predicting portal thrombosis in cirrhosis: Some Issues.
    J Hepatol. 2021 Aug 27. pii: S0168-8278(21)02010.
    PubMed    


  396. RICKE J, Schinner R, Seidensticker M, Gasbarrini A, et al
    Liver function after combined selective internal radiation therapy or sorafenib monotherapy in advanced hepatocellular carcinoma.
    J Hepatol. 2021 Aug 26. pii: S0168-8278(21)02003.
    PubMed     Abstract available


  397. THULUVATH PJ, Robarts P, Chauhan M
    Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases.
    J Hepatol. 2021 Aug 26. pii: S0168-8278(21)02002.
    PubMed     Abstract available


  398. BLOOM P, Tapper EB, Young VB, Lok AS, et al
    Microbiome Therapeutics for Hepatic Encephalopathy.
    J Hepatol. 2021 Aug 25. pii: S0168-8278(21)01998.
    PubMed     Abstract available


  399. WANG H, Zhang H, Wang Y, Brown ZJ, et al
    Regulatory T cell and neutrophil extracellular trap interaction contributes to carcinogenesis in non-alcoholic steatohepatitis.
    J Hepatol. 2021 Aug 4. pii: S0168-8278(21)01962.
    PubMed     Abstract available


  400. WANG J, Hou Z, Liu J, Gu Y, et al
    Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): A multicenter study.
    J Hepatol. 2021;75:439-441.
    PubMed     Abstract available


  401. NACHIT M, Kwanten WJ, Thissen JP, Op De Beeck B, et al
    Muscle fat content is strongly associated with NASH: A longitudinal study in patients with morbid obesity.
    J Hepatol. 2021;75:292-301.
    PubMed     Abstract available


  402. TAVABIE OD, Karvellas CJ, Salehi S, Speiser JL, et al
    A novel microRNA-based prognostic model outperforms standard prognostic models in patients with acetaminophen-induced acute liver failure.
    J Hepatol. 2021;75:424-434.
    PubMed     Abstract available


  403. ASHBY K, Zhuang W, Gonzalez-Jimenez A, Alvarez-Alvarez I, et al
    Elevated bilirubin, alkaline phosphatase at onset, and drug metabolism are associated with prolonged recovery from DILI.
    J Hepatol. 2021;75:333-341.
    PubMed     Abstract available


  404. MARTINEZ J, Hernandez-Gea V, Rodriguez-de-Santiago E, Tellez L, et al
    Bacterial infections in patients with acute variceal bleeding in the era of antibiotic prophylaxis.
    J Hepatol. 2021;75:342-350.
    PubMed     Abstract available


  405. YANG Y, Sangwung P, Kondo R, Jung Y, et al
    Alcohol-induced Hsp90 acetylation is a novel driver of liver sinusoidal endothelial dysfunction and alcohol-related liver disease.
    J Hepatol. 2021;75:377-386.
    PubMed     Abstract available


    July 2021
  406. TORGERSEN J, Newcomb CW, Carbonari DM, Rentsch CT, et al
    Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation.
    J Hepatol. 2021 Jul 29. pii: S0168-8278(21)01950.
    PubMed     Abstract available


  407. TURON F, Driever EG, Baiges A, Cerda E, et al
    Predicting portal thrombosis in cirrhosis: A prospective study of clinical, ultrasonographic and hemostatic factors.
    J Hepatol. 2021 Jul 29. pii: S0168-8278(21)01946.
    PubMed     Abstract available


  408. CARPINO G, Cardinale V, Di Giamberardino A, Overi D, et al
    Thrombospondin 1 and 2 along with PEDF inhibit angiogenesis and promote lymphangiogenesis in intrahepatic cholangiocarcinoma.
    J Hepatol. 2021 Jul 27. pii: S0168-8278(21)01947.
    PubMed     Abstract available


  409. GALLE PR, Abou-Alfa G
    Decision making in systemic therapy of hepatocellular carcinoma: should we pay attention to disease etiology?
    J Hepatol. 2021 Jul 23. pii: S0168-8278(21)01913.
    PubMed    


  410. SCHULTALBERS M, Grote-Koska D, Cornberg M, Schmidt JJ, et al
    Plasma and ascites pharmacokinetic of meropenem in patients with decompensated liver cirrhosis and spontaneous bacterial peritonitis.
    J Hepatol. 2021 Jul 23. pii: S0168-8278(21)01914.
    PubMed    


  411. BRISSOT P, Loreal O
    Hemochromatoses.
    J Hepatol. 2021 Jul 11. pii: S0168-8278(21)00226.
    PubMed    


  412. BRUIX J, Chan SL, Galle PR, Rimassa L, et al
    Systemic treatment of hepatocellular carcinoma. An EASL position paper.
    J Hepatol. 2021 Jul 10. pii: S0168-8278(21)01903.
    PubMed     Abstract available


  413. VAQUERO J, Keitel V
    Deciphering FAK in intrahepatic cholangiocarcinoma: a novel therapeutic target?
    J Hepatol. 2021 Jul 9. pii: S0168-8278(21)01902.
    PubMed    


  414. CLARIA J, Curto A, Moreau R, Colsch B, et al
    Untargeted lipidomics uncovers lipid signatures distinguishing severe versus moderate forms of acutely decompensated cirrhosis.
    J Hepatol. 2021 Jul 7. pii: S0168-8278(21)01895.
    PubMed     Abstract available


  415. ZHU C, Boucheron N, Muller AC, Majek P, et al
    24-NorUrsodeoxycholic acid reshapes immunometabolism in CD8(+) T-cells and alleviates hepatic inflammation.
    J Hepatol. 2021 Jul 6. pii: S0168-8278(21)01886.
    PubMed     Abstract available


  416. BETTINGER D, Thimme R, Schultheiss M
    Reply: TIPS and liver transplantation should always be discussed together.
    J Hepatol. 2021 Jul 6. pii: S0168-8278(21)01891.
    PubMed    


  417. SLADKY VC, Eichin F, Reiberger T, Villunger A, et al
    Polyploidy control in hepatic health and disease.
    J Hepatol. 2021 Jul 3. pii: S0168-8278(21)01879.
    PubMed     Abstract available


  418. ALVARADO-TAPIAS E, Vilades D, Brujats A, Villanueva C, et al
    Reply letter to correspondence entitled: "Non-selective beta blockers and mortality in decompensated Cirrhosis: Is Cirrhotic Cardiomyopathy the missing link?"
    J Hepatol. 2021 Jul 2. pii: S0168-8278(21)01846.
    PubMed    


  419. VAN DER MERWE S, Chokshi S, Bernsmeier C, Albillos A, et al
    The multifactorial mechanisms of bacterial infection in decompensated cirrhosis.
    J Hepatol. 2021;75 Suppl 1:S82-S100.
    PubMed     Abstract available


  420. TREBICKA J, Macnaughtan J, Schnabl B, Shawcross DL, et al
    The microbiota in cirrhosis and its role in hepatic decompensation.
    J Hepatol. 2021;75 Suppl 1:S67-S81.
    PubMed     Abstract available


  421. ENGELMANN C, Claria J, Szabo G, Bosch J, et al
    Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction.
    J Hepatol. 2021;75 Suppl 1:S49-S66.
    PubMed     Abstract available


  422. JEPSEN P, Younossi ZM
    The global burden of cirrhosis: A review of disability-adjusted life-years lost and unmet needs.
    J Hepatol. 2021;75 Suppl 1:S3-S13.
    PubMed     Abstract available


  423. TANDON P, Montano-Loza AJ, Lai JC, Dasarathy S, et al
    Sarcopenia and frailty in decompensated cirrhosis.
    J Hepatol. 2021;75 Suppl 1:S147-S162.
    PubMed     Abstract available


  424. JALAN R, D'Amico G, Trebicka J, Moreau R, et al
    New clinical and pathophysiological perspectives defining the trajectory of cirrhosis.
    J Hepatol. 2021;75 Suppl 1:S14-S26.
    PubMed     Abstract available


  425. GARCIA-PAGAN JC, Francoz C, Montagnese S, Senzolo M, et al
    Management of the major complications of cirrhosis: Beyond guidelines.
    J Hepatol. 2021;75 Suppl 1:S135-S146.
    PubMed     Abstract available


  426. CARACENI P, Abraldes JG, Gines P, Newsome PN, et al
    The search for disease-modifying agents in decompensated cirrhosis: From drug repurposing to drug discovery.
    J Hepatol. 2021;75 Suppl 1:S118-S134.
    PubMed     Abstract available


  427. FERNANDEZ J, Piano S, Bartoletti M, Wey EQ, et al
    Management of bacterial and fungal infections in cirrhosis: The MDRO challenge.
    J Hepatol. 2021;75 Suppl 1:S101-S117.
    PubMed     Abstract available


  428. JALAN R, Szabo G
    New concepts and perspectives in decompensated cirrhosis.
    J Hepatol. 2021;75 Suppl 1:S1-S2.
    PubMed    


  429. KREMOSER C
    FXR agonists for NASH: How are they different and what difference do they make?
    J Hepatol. 2021;75:12-15.
    PubMed    


  430. LIU Y, Xu N, Ji H
    Reply to: "Myofibroblast YAP/TAZ is dispensable for liver fibrosis in mice".
    J Hepatol. 2021;75:241-243.
    PubMed    


  431. BOSCH J
    Reply to: "Achieving an effective pressure reduction after TIPS: The need for a new target".
    J Hepatol. 2021;75:248-249.
    PubMed    


  432. STAUBER RE, Scharnagl H, Marsche G
    Reply to: "Prognostic value of HDL-related biomarkers in patients with HBV-related ACLF".
    J Hepatol. 2021;75:245-246.
    PubMed    


  433. SIMBRUNNER B, Costa D, Reiberger T
    Reply to: "Presepsin as a biomarker of inflammation and prognosis in decompensated liver disease".
    J Hepatol. 2021;75:234-236.
    PubMed    


  434. XU L, Wettschureck N, Bai Y, Yuan Z, et al
    Myofibroblast YAP/TAZ is dispensable for liver fibrosis in mice.
    J Hepatol. 2021;75:238-241.
    PubMed    


  435. WEN X, Tong J, Yao M, Hu J, et al
    Prognostic value of HDL-related biomarkers in patients with HBV-related ACLF.
    J Hepatol. 2021;75:243-245.
    PubMed    


  436. WANG X, Luo X, Yang L
    Achieving an effective pressure reduction after TIPS: The need for a new target.
    J Hepatol. 2021;75:246-248.
    PubMed    


  437. FERRARESE A, Plebani M, Frigo AC, Burra P, et al
    Presepsin as a biomarker of inflammation and prognosis in decompensated liver disease.
    J Hepatol. 2021;75:232-234.
    PubMed    


  438. BEUERS U
    EASL recognition award recipient 2021: Prof. Dieter Haussinger.
    J Hepatol. 2021;75:7-9.
    PubMed    


  439. ROMERO-GOMEZ M
    EASL international recognition award recipient 2021: Prof. Dr. Nahum Mendez-Sanchez.
    J Hepatol. 2021;75:10-11.
    PubMed    


  440. MENDEZ-SANCHEZ N, Diaz-Orozco L, Cordova-Gallardo J
    Redefinition of fatty liver disease from NAFLD to MAFLD raised disease awareness: Mexican experience.
    J Hepatol. 2021;75:221-222.
    PubMed    


  441. PETERS L, Burkert S, Gruner B
    Parasites of the liver - epidemiology, diagnosis and clinical management in the European context.
    J Hepatol. 2021;75:202-218.
    PubMed     Abstract available


  442. SIMON J, Goikoetxea-Usandizaga N, Serrano-Macia M, Fernandez-Ramos D, et al
    Magnesium accumulation upon cyclin M4 silencing activates microsomal triglyceride transfer protein improving NASH.
    J Hepatol. 2021;75:34-45.
    PubMed     Abstract available


  443. LIU C, Zhou B, Meng M, Zhao W, et al
    FOXA3 induction under endoplasmic reticulum stress contributes to non-alcoholic fatty liver disease.
    J Hepatol. 2021;75:150-162.
    PubMed     Abstract available


  444. STEPHENS C, Robles-Diaz M, Medina-Caliz I, Garcia-Cortes M, et al
    Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry.
    J Hepatol. 2021;75:86-97.
    PubMed     Abstract available


  445. GUSTOT T, Stadlbauer V, Laleman W, Alessandria C, et al
    Transition to decompensation and acute-on-chronic liver failure: Role of predisposing factors and precipitating events.
    J Hepatol. 2021;75 Suppl 1:S36-S48.
    PubMed     Abstract available


  446. MOREAU R, Gao B, Papp M, Banares R, et al
    Acute-on-chronic liver failure: A distinct clinical syndrome.
    J Hepatol. 2021;75 Suppl 1:S27-S35.
    PubMed     Abstract available


  447. BURRA P, Samuel D, Sundaram V, Duvoux C, et al
    Limitations of current liver donor allocation systems and the impact of newer indications for liver transplantation.
    J Hepatol. 2021;75 Suppl 1:S178-S190.
    PubMed     Abstract available


  448. BERNAL W, Karvellas C, Saliba F, Saner FH, et al
    Intensive care management of acute-on-chronic liver failure.
    J Hepatol. 2021;75 Suppl 1:S163-S177.
    PubMed     Abstract available


    June 2021
  449. MA L, Wang L, Khatib SA, Chang CW, et al
    Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
    J Hepatol. 2021 Jun 30. pii: S0168-8278(21)01848.
    PubMed     Abstract available


  450. VITHAYATHIL M, Bridegwater J, Khan SA
    Medical therapies for intra-hepatic cholangiocarcinoma.
    J Hepatol. 2021 Jun 29. pii: S0168-8278(21)00238.
    PubMed    


  451. QUITT O, Luo S, Meyer M, Xie Z, et al
    T-cell engager antibodies enable T cells to control HBV infection and to target HBsAg-positive hepatoma in mice.
    J Hepatol. 2021 Jun 22. pii: S0168-8278(21)00443.
    PubMed     Abstract available


  452. D'AMICO G, Bernardi M, Angeli P
    TOWARDS A NEW DEFINITION OF DECOMPENSATED CIRRHOSIS.
    J Hepatol. 2021 Jun 19. pii: S0168-8278(21)00438.
    PubMed     Abstract available


  453. BOU SALEH M, Louvet A, Ntandja-Wandji LC, Boleslawski E, et al
    Loss of hepatocyte identity following aberrant YAP activation: a key mechanism in alcoholic hepatitis.
    J Hepatol. 2021 Jun 12. pii: S0168-8278(21)00416.
    PubMed     Abstract available


  454. GEIDL-FLUECK B, Gerber PA
    Reply to Comments on "Fructose- and sucrose- but not glucose-sweetened beverages promote hepatic de novo lipogenesis - A randomized controlled trial".
    J Hepatol. 2021 Jun 12. pii: S0168-8278(21)00418.
    PubMed    


  455. SELLAU J, Groneberg M, Hoenow S, Lotter H, et al
    The underlying cellular immune pathology of Entamoeba histolytica-induced hepatic amoebiasis.
    J Hepatol. 2021 Jun 11. pii: S0168-8278(21)00221.
    PubMed    


  456. WU J, Li H, Xu Z, Ran L, et al
    Population-specific cut-off points of fatty liver index for the diagnosis of hepatic steatosis.
    J Hepatol. 2021 Jun 9. pii: S0168-8278(21)00413.
    PubMed    


  457. CORPECHOT C
    Reply to: "Chronic fatigue should not be overlooked in primary biliary cholangitis".
    J Hepatol. 2021 Jun 6. pii: S0168-8278(21)00404.
    PubMed    


  458. FLEMMING JA, Velez MP
    The ART of medicine: Counselling women with liver disease about assisted reproductive technology.
    J Hepatol. 2021;74:1283-1285.
    PubMed    


  459. KUMAR R, Jalan R
    Reply to: "Failure to control variceal bleeding: Definition matters".
    J Hepatol. 2021;74:1492-1493.
    PubMed    


  460. BAIGES A, Bureau C, Garcia-Pagan JC
    Failure to control variceal bleeding: Definition matters.
    J Hepatol. 2021;74:1491-1492.
    PubMed    


  461. BERNAL W, McPhail MJ
    Acute liver failure.
    J Hepatol. 2021;74:1489-1490.
    PubMed    


  462. GILGENKRANTZ H, Mallat A, Moreau R, Lotersztajn S, et al
    Targeting cell-intrinsic metabolism for antifibrotic therapy.
    J Hepatol. 2021;74:1442-1454.
    PubMed     Abstract available


  463. BRUIX J
    Endpoints in clinical trials for liver cancer and their value in evidence-based clinical decision making: An unresolved Gordian knot.
    J Hepatol. 2021;74:1483-1488.
    PubMed     Abstract available


  464. BETTINGER D, Sturm L, Pfaff L, Hahn F, et al
    Refining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival.
    J Hepatol. 2021;74:1362-1372.
    PubMed     Abstract available


  465. CADOUX M, Caruso S, Pham S, Gougelet A, et al
    Expression of NKG2D ligands is downregulated by beta-catenin signalling and associates with HCC aggressiveness.
    J Hepatol. 2021;74:1386-1397.
    PubMed     Abstract available


  466. WEI G, Cao J, Huang P, An P, et al
    Synthetic human ABCB4 mRNA therapy rescues severe liver disease phenotype in a BALB/c.Abcb4(-/-) mouse model of PFIC3.
    J Hepatol. 2021;74:1416-1428.
    PubMed     Abstract available


  467. ABDALLAH MA, Kuo YF, Asrani S, Wong RJ, et al
    Validating a novel score based on interaction between ACLF grade and MELD score to predict waitlist mortality.
    J Hepatol. 2021;74:1355-1361.
    PubMed     Abstract available


    May 2021
  468. KOLAMUNNAGE-DONA R, Berhane S, Potts H, Williams EH, et al
    Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma.
    J Hepatol. 2021 May 27. pii: S0168-8278(21)00350.
    PubMed     Abstract available


  469. RUDLER M, Savier E, Alioua I, Sultanik P, et al
    TIPS and liver transplantation should always be discussed together.
    J Hepatol. 2021 May 26. pii: S0168-8278(21)00347.
    PubMed    


  470. BAUMERT TF
    "We can and should do better" - an interview with the 2020 Nobel prize laureates who revolutionized hepatology.
    J Hepatol. 2021 May 25. pii: S0168-8278(21)00312.
    PubMed    


  471. CORNBERG M, Eberhardt CS
    Protected or not protected, that is the question - First data on COVID-19 vaccine responses in patients with NAFLD and liver transplant recipients.
    J Hepatol. 2021 May 25. pii: S0168-8278(21)00342.
    PubMed    


  472. CORDELL HJ, Fryett JJ, Ueno K, Darlay R, et al
    An international genome-wide meta-analysis of primary biliary cholangitis: novel risk loci and candidate drugs.
    J Hepatol. 2021 May 22. pii: S0168-8278(21)00334.
    PubMed     Abstract available


  473. WANG H, Wen B, Chen J
    "Small esophageal varices in compensated cirrhosis patients: to treat or not to treat?" -Reply.
    J Hepatol. 2021 May 18. pii: S0168-8278(21)00335.
    PubMed    


  474. NAN Y, An J, Bao J, Chen H, et al
    The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease.
    J Hepatol. 2021 May 18. pii: S0168-8278(21)00332.
    PubMed     Abstract available


  475. ZHOU HC, Liu CX, Pan WD, Shang LR, et al
    Dual and opposing roles of the androgen receptor in VETC-dependent and invasion-dependent metastasis of hepatocellular carcinoma.
    J Hepatol. 2021 May 15. pii: S0168-8278(21)00331.
    PubMed     Abstract available


  476. PINYOL R, Torrecilla S, Wang H, Montironi C, et al
    Molecular characterization of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis.
    J Hepatol. 2021 May 13. pii: S0168-8278(21)00326.
    PubMed     Abstract available


  477. TRAMPERT DC, van de Graaf SFJ, Jongejan A, Oude Elferink RPJ, et al
    Erratum to: "Hepatobiliary acid-base homeostasis: Insights from analogous secretory epithelia" (J Hepatol 2021; 74: 428-441).
    J Hepatol. 2021 May 12. pii: S0168-8278(21)00330.
    PubMed    


  478. KUDO M, Matilla A, Santoro A, Melero I, et al
    CheckMate 040 Cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis.
    J Hepatol. 2021 May 12. pii: S0168-8278(21)00313.
    PubMed     Abstract available


  479. ROMBAUT M, Boeckmans J, Rodrigues RM, van Grunsven LA, et al
    Direct reprogramming of somatic cells into induced hepatocytes: cracking the Enigma code.
    J Hepatol. 2021 May 11. pii: S0168-8278(21)00314.
    PubMed     Abstract available


  480. YEO YH, Hwang J, Jeong D, Dang N, et al
    Surveillance of patients with cirrhosis remains suboptimal in the United States.
    J Hepatol. 2021 May 6. pii: S0168-8278(21)00307.
    PubMed     Abstract available


  481. HYUN J, Al Abo M, Dutta RK, Oh SH, et al
    Dysregulation of the ESRP2-NF2-YAP/TAZ axis promotes hepatobiliary carcinogenesis in non-alcoholic fatty liver disease.
    J Hepatol. 2021 May 5. pii: S0168-8278(21)00298.
    PubMed     Abstract available


  482. CABRE N, Luciano-Mateo F, Chapski DJ, Baiges-Gaya G, et al
    Glutaminolysis-induced mTORC1 activation drives non-alcoholic steatohepatitis progression.
    J Hepatol. 2021 May 4. pii: S0168-8278(21)00302.
    PubMed     Abstract available


  483. JOHNSON PJ
    In search of an evidence base for HCC surveillance: Purity or pragmatism?
    J Hepatol. 2021;74:1025-1027.
    PubMed    


  484. ARROYO V, Fernandez J, Moreau R
    Reply to: "Systemic inflammation and disorders of hemostasis in the AD-ACLF syndrome".
    J Hepatol. 2021;74:1265-1267.
    PubMed    


  485. COENRAAD MJ, Artru F
    Amino acids in acute-on-chronic liver failure: Another piece of the puzzle?
    J Hepatol. 2021;74:1015-1017.
    PubMed    


  486. ESLAM M, George J
    MAFLD: Now is the time to capitalize on the momentum.
    J Hepatol. 2021;74:1262-1263.
    PubMed    


  487. FOUAD Y, Gomaa A, Semida N, Ghany WA, et al
    Change from NAFLD to MAFLD increases the awareness of fatty liver disease in primary care physicians and specialists.
    J Hepatol. 2021;74:1254-1256.
    PubMed    


  488. ALEM SA, Gaber Y, Abdalla M, Said E, et al
    Capturing patient experience: A qualitative study of change from NAFLD to MAFLD real-time feedback.
    J Hepatol. 2021;74:1261-1262.
    PubMed    


  489. KASPER P, Martin A, Lang S, Demir M, et al
    Hypertension in NAFLD: An uncontrolled burden.
    J Hepatol. 2021;74:1258-1260.
    PubMed    


  490. SPEARMAN CW, Desalegn H, Ocama P, Awuku YA, et al
    The sub-Saharan Africa position statement on the redefinition of fatty liver disease: From NAFLD to MAFLD.
    J Hepatol. 2021;74:1256-1258.
    PubMed    


  491. ZHANG Y, Lu Z, Zeng W, Zhao J, et al
    Two sides of NNMT in alcoholic and non-alcoholic fatty liver development.
    J Hepatol. 2021;74:1250-1253.
    PubMed    


  492. ZACCHERINI G, Aguilar F, Caraceni P, Claria J, et al
    Assessing the role of amino acids in systemic inflammation and organ failure in patients with ACLF.
    J Hepatol. 2021;74:1117-1131.
    PubMed     Abstract available


  493. WANG T, Chen K, Yao W, Zheng R, et al
    Acetylation of lactate dehydrogenase B drives NAFLD progression by impairing lactate clearance.
    J Hepatol. 2021;74:1038-1052.
    PubMed     Abstract available


    April 2021
  494. IZZY M, Lin G, Watt KD
    Non-selective beta blockers and mortality in decompensated Cirrhosis: Is Cirrhotic Cardiomyopathy the missing link?
    J Hepatol. 2021 Apr 28. pii: S0168-8278(21)00260.
    PubMed    


  495. SENZOLO M, Garcia-Tsao G, Garcia-Pagan JC
    Current knowledge and management of portal vein thrombosis in cirrhosis.
    J Hepatol. 2021 Apr 27. pii: S0168-8278(21)00265.
    PubMed     Abstract available


  496. BETTINGER D, Kloeckner R, Boettler T, Thimme R, et al
    Reply: Freiburg index of post-TIPS survival (FIPS) a valid prognostic score in patients with cirrhosis but also an advisor against TIPS?
    J Hepatol. 2021 Apr 26. pii: S0168-8278(21)00264.
    PubMed    


  497. VILLANUEVA C, Albillos A, Genesca J, Garcia-Pagan JC, et al
    Bacterial infections adversely influence the risk of decompensation and survival in compensated cirrhosis.
    J Hepatol. 2021 Apr 24. pii: S0168-8278(21)00257.
    PubMed     Abstract available


  498. BELLI LS, Duvoux C, Artzner T, Bernal W, et al
    Liver transplantation for patients with acute-on-chronic liver failure (ACLF) in Europe: results of the ELITA/EF-CLIF collaborative study (ECLIS).
    J Hepatol. 2021 Apr 24. pii: S0168-8278(21)00261.
    PubMed     Abstract available


  499. GINES P
    Robert W Schrier, an influential observer from outside Hepatology (1936-2021).
    J Hepatol. 2021 Apr 20. pii: S0168-8278(21)00180.
    PubMed    


  500. TAPPER EB, Nikirk S, Parikh N, Zhao L, et al
    Falls are common, morbid, and predictable in patients with cirrhosis.
    J Hepatol. 2021 Apr 19. pii: S0168-8278(21)00247.
    PubMed     Abstract available


  501. OOI GJ, Meikle PJ, Huynh K, Earnest A, et al
    Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis.
    J Hepatol. 2021 Apr 19. pii: S0168-8278(21)00248.
    PubMed     Abstract available


  502. TANAKA A, Hirohara J, Nakano T, Matsumoto K, et al
    Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis.
    J Hepatol. 2021 Apr 18. pii: S0168-8278(21)00245.
    PubMed     Abstract available


  503. GOLSE N, Vibert E, Vignon-Clementel IE
    Comments on: "A step forward to predict the risk of post-hepatectomy portal hypertension".
    J Hepatol. 2021 Apr 15. pii: S0168-8278(21)00242.
    PubMed    


  504. SUNDARAM V
    Characterizing bacterial infections in acute-on-chronic liver failure among patients with cirrhosis from nonalcoholic steatohepatitis.
    J Hepatol. 2021 Apr 13. pii: S0168-8278(21)00240.
    PubMed    


  505. CRAMER T, Vaupel P
    Is tissue hypoxia the principle mechanism for immune evasion and malignant progression in Hepatocellular Carcinoma?
    J Hepatol. 2021 Apr 8. pii: S0168-8278(21)00228.
    PubMed    


  506. PRINZ P
    Comments on "fructose- and sucrose- but not glucose-sweetened beverages promote hepatic de novo lipogenesis - A randomized controlled trial".
    J Hepatol. 2021 Apr 5. pii: S0168-8278(21)00225.
    PubMed    


  507. DESSEIN A
    Clinical utility of polygenic risk scores for predicting NAFLD disorders.
    J Hepatol. 2021;74:769-770.
    PubMed    


  508. COSTA D, Simbrunner B, Reiberger T
    Reply to: "Prognostic role of systemic inflammatory biomarkers in advanced chronic liver disease".
    J Hepatol. 2021;74:1000-1001.
    PubMed    


  509. HOBEIKA C, Fuks D
    Reply to: "Letter regarding Benchmark performance of laparoscopic left lateral sectionectomy and right hepatectomy in expert centers".
    J Hepatol. 2021;74:987-988.
    PubMed    


  510. HEGARTY R, Singh S, Bansal S, Fitzpatrick E, et al
    NAFLD to MAFLD in adults but the saga continues in children: an opportunity to advocate change.
    J Hepatol. 2021;74:991-992.
    PubMed    


  511. ESLAM M, Ratziu V, George J
    Yet more evidence that MAFLD is more than a name change.
    J Hepatol. 2021;74:977-979.
    PubMed    


  512. ESLAM M, George J
    MAFLD: A holistic view to redefining fatty liver disease.
    J Hepatol. 2021;74:983-985.
    PubMed    


  513. ESLAM M, George J
    MAFLD: A game changer redefining fatty liver disease for adults and children.
    J Hepatol. 2021;74:992-994.
    PubMed    


  514. AMPUERO J, Gallego-Duran R, Romero-Gomez M
    Reply to: "The predictive value of significant fibrosis for metabolic disturbances in patients with NAFLD".
    J Hepatol. 2021;74:971-972.
    PubMed    


  515. ZHENG KI, Sun DQ, Jin Y, Zhu PW, et al
    Clinical utility of the MAFLD definition.
    J Hepatol. 2021;74:989-991.
    PubMed    


  516. DEBNATH P, Rathi P
    Prognostic role of systemic inflammatory biomarkers in advanced chronic liver disease.
    J Hepatol. 2021;74:999-1000.
    PubMed    


  517. MORENO C, Sheron N, Tiniakos D, Lackner C, et al
    "Dual aetiology fatty liver disease": A recently proposed term associated with potential pitfalls.
    J Hepatol. 2021;74:979-982.
    PubMed    


  518. BAFFY G
    Is the name 'NAFLD' too big to fail? Let's keep it for 'nutrition-associated fatty liver disease'.
    J Hepatol. 2021;74:988.
    PubMed    


  519. XIA M, Zeng H, Wang S, Tang H, et al
    Insights into contribution of genetic variants towards the susceptibility of MAFLD revealed by the NMR-based lipoprotein profiling.
    J Hepatol. 2021;74:974-977.
    PubMed    


  520. LIU M, Sun L, Mao Y
    The predictive value of significant fibrosis for metabolic disturbances in patients with NAFLD.
    J Hepatol. 2021;74:970-971.
    PubMed    


  521. SINGH SP, Anirvan P, Reddy KR, Conjeevaram HS, et al
    Non-alcoholic fatty liver disease: Not time for an obituary just yet!
    J Hepatol. 2021;74:972-974.
    PubMed    


  522. PONIACHIK J, Roblero JP, Urzua A, Cattaneo M, et al
    A new definition for non-alcoholic fatty liver disease.
    J Hepatol. 2021;74:982-983.
    PubMed    


  523. RUSSOLILLO N, Aldrighetti L, Guglielmi A, Giuliante F, et al
    Correspondence on "Benchmark performance of laparoscopic left lateral sectionectomy and right hepatectomy in expert centers".
    J Hepatol. 2021;74:985-986.
    PubMed    


  524. RIMASSA L, Personeni N, Czauderna C, Foerster F, et al
    Systemic treatment of HCC in special populations.
    J Hepatol. 2021;74:931-943.
    PubMed     Abstract available


  525. COSTA D, Simbrunner B, Jachs M, Hartl L, et al
    Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality.
    J Hepatol. 2021;74:819-828.
    PubMed     Abstract available


    March 2021
  526. MONTAGNESE S, Lauridsen M, Vilstrup H, Zarantonello L, et al
    A pilot study of Golexanolone, a new GABA-A receptor modulating steroid antagonist, in patients with covert hepatic encephalopathy.
    J Hepatol. 2021 Mar 24. pii: S0168-8278(21)00184.
    PubMed     Abstract available


  527. LI J, Zhu X, Zhang M, Zhang Y, et al
    Limb expression 1-like (LIX1L) protein promotes cholestatic liver injury by regulating bile acid metabolism.
    J Hepatol. 2021 Mar 18. pii: S0168-8278(21)00177.
    PubMed     Abstract available


  528. LUJAMBIO A, Maina F
    Turning up our understanding of liver cancer by a notch.
    J Hepatol. 2021;74:502-504.
    PubMed    


  529. JOYE R, Lador F, Aggoun Y, Farhat N, et al
    Outcome of paediatric portopulmonary hypertension in the modern management era: A case report of 6 patients.
    J Hepatol. 2021;74:742-747.
    PubMed     Abstract available


  530. HEINRICH S, Craig AJ, Ma L, Heinrich B, et al
    Understanding tumour cell heterogeneity and its implication for immunotherapy in liver cancer using single-cell analysis.
    J Hepatol. 2021;74:700-715.
    PubMed     Abstract available


  531. MOZZANEGA B
    Ulipristal acetate and liver-injuries: while Esmya is revoked, EllaOne is allowed in repeated self-administrations possibly exceeding UPA toxic-dosing with Esmya.
    J Hepatol. 2021;74:750-751.
    PubMed    


  532. CHAND D, Mohr F, McMillan H, Tukov FF, et al
    Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy.
    J Hepatol. 2021;74:560-566.
    PubMed     Abstract available


  533. MUTANEN A, Lohi J, Merras-Salmio L, Koivusalo A, et al
    Prediction, identification and progression of histopathological liver disease activity in children with intestinal failure.
    J Hepatol. 2021;74:593-602.
    PubMed     Abstract available


    February 2021
  534. SHAHINI E, Ahmed F
    Chronic fatigue should not be overlooked in primary biliary cholangitis.
    J Hepatol. 2021 Feb 25. pii: S0168-8278(21)00154.
    PubMed    


  535. GUDD CL, Au L, Triantafyllou E, Shum B, et al
    Activation and transcriptional profile of monocytes and CD8+ T cells are altered in checkpoint inhibitor-related hepatitis.
    J Hepatol. 2021 Feb 22. pii: S0168-8278(21)00108.
    PubMed     Abstract available


  536. MALLET V
    Intravenous ketamine and progressive cholangiopathy in Covid-19 patients.
    J Hepatol. 2021 Feb 19. pii: S0168-8278(21)00107.
    PubMed    


  537. BARTOLI A, Gitto S, Sighinolfi P, Cursaro C, et al
    PRIMARY BILIARY CHOLANGITIS ASSOCIATED WITH SARS-COV2 INFECTION.
    J Hepatol. 2021 Feb 18. pii: S0168-8278(21)00106.
    PubMed    


  538. RIPOLL C, Zipprich A
    Open or closed window: That is the question.
    J Hepatol. 2021;74:485-486.
    PubMed    


  539. ANAND A, Kumar R, Shalimar
    PREDICTing acute-on-chronic liver failure in patients with acute decompensation.
    J Hepatol. 2021;74:478-479.
    PubMed    


  540. HERNAEZ R, Kanwal F
    Reply to: "The role of the model for end-stage liver disease sodium score and joint models for 90-day mortality prediction in in patients with acute-on-chronic liver failure".
    J Hepatol. 2021;74:477.
    PubMed    


  541. GOUDSMIT BFJ, Tushuizen ME, Putter H, Braat AE, et al
    The role of the model for end-stage liver disease-sodium score and joint models for 90-day mortality prediction in patients with acute-on-chronic liver failure.
    J Hepatol. 2021;74:475-476.
    PubMed    


  542. MANCO R, Itzkovitz S
    Liver zonation.
    J Hepatol. 2021;74:466-468.
    PubMed    


  543. SAWATZKI M, Guller U, Gusewell S, Husarik DB, et al
    Contrast-enhanced ultrasound can guide the therapeutic strategy by improving the detection of colorectal liver metastases.
    J Hepatol. 2021;74:419-427.
    PubMed     Abstract available


  544. WINKLER M, Staniczek T, Kurschner SW, Schmid CD, et al
    Endothelial GATA4 controls liver fibrosis and regeneration by preventing a pathogenic switch in angiocrine signaling.
    J Hepatol. 2021;74:380-393.
    PubMed     Abstract available


  545. WONG F, Piano S, Singh V, Bartoletti M, et al
    Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure.
    J Hepatol. 2021;74:330-339.
    PubMed     Abstract available


    January 2021
  546. CONDE DE LA ROSA L, Garcia-Ruiz C, Vallejo C, Baulies A, et al
    STARD1 promotes NASH-driven HCC by sustaining the generation of bile acids through the alternative mitochondrial pathway.
    J Hepatol. 2021 Jan 27. pii: S0168-8278(21)00040.
    PubMed     Abstract available


  547. SCHATTENBERG JM, Pares A, Kowdley KV, Heneghan MA, et al
    A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA.
    J Hepatol. 2021 Jan 20. pii: S0168-8278(21)00022.
    PubMed     Abstract available


  548. RACHWAN RJ, Kutkut I, Timsina LR, Bou Chaaya RG, et al
    CAD-LT score effectively predicts risk of significant coronary artery disease in liver transplant candidates.
    J Hepatol. 2021 Jan 18. pii: S0168-8278(21)00016.
    PubMed     Abstract available


  549. RAHIM MN, Theocharidou E, Yen Lau KG, Ahmed R, et al
    Safety and efficacy of in vitro fertilisation in patients with chronic liver disease and liver transplantation recipients.
    J Hepatol. 2021 Jan 15. pii: S0168-8278(21)00005.
    PubMed     Abstract available


  550. FORLANO R, Mullish BH, Maurice JB, Thursz MR, et al
    NAFLD: Time to apply quantitation in liver biopsies as endpoints in clinical trials.
    J Hepatol. 2021;74:241-242.
    PubMed    


  551. WU Y, Kumar R, Huang J, Wang M, et al
    FIB-4 cut-off should be re-evaluated in patients with metabolic associated fatty liver disease (MAFLD).
    J Hepatol. 2021;74:247-248.
    PubMed    


  552. NAYAGAM JS, Strautnieks S, Joshi D, Thompson RJ, et al
    Challenges in understanding the consequences of variants in ABCB4 gene.
    J Hepatol. 2021;74:242-243.
    PubMed    


  553. TSOCHATZIS EA, Srivastava A, Rosenberg W
    Reply to: "FIB-4 cut-off should be re-evaluated in patients with metabolic associated fatty liver disease (MAFLD)".
    J Hepatol. 2021;74:248-249.
    PubMed    


  554. SAVALE L, Sitbon O
    Reply to: "Management of portopulmonary hypertension: What is more important, PAH severity or liver disease severity?"
    J Hepatol. 2021;74:238-239.
    PubMed    


  555. KOLHE K, Tripathi DM, Kaur S
    Management of portopulmonary hypertension: What is more important, PAH severity or liver disease severity?
    J Hepatol. 2021;74:237-238.
    PubMed    


  556. STATTERMAYER AF, Ferenci P, Trauner M
    Reply to: "Challenges in understanding the consequences of variants in ABCB4 gene".
    J Hepatol. 2021;74:244-245.
    PubMed    


  557. COZMESCU AC, Counsell J, Gissen P
    Gene therapies targeting the liver.
    J Hepatol. 2021;74:235-236.
    PubMed    


  558. BOSCH J
    Small diameter shunts should lead to safe expansion of the use of TIPS.
    J Hepatol. 2021;74:230-234.
    PubMed     Abstract available


  559. DWYER BJ, Macmillan MT, Brennan PN, Forbes SJ, et al
    Cell therapy for advanced liver diseases: Repair or rebuild.
    J Hepatol. 2021;74:185-199.
    PubMed     Abstract available


  560. TEO K, Abeysekera KWM, Adams L, Aigner E, et al
    rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis.
    J Hepatol. 2021;74:20-30.
    PubMed     Abstract available


    October 2020
  561. CARBONE M, Ronca V, Invernizzi P
    Reply to: "A spotlight on natural killer cells in primary biliary cholangitis".
    J Hepatol. 2020 Oct 14. pii: S0168-8278(20)33663.
    PubMed    


  562. HYDES T, Khakoo SI
    A spotlight on natural killer cells in primary biliary cholangitis.
    J Hepatol. 2020 Oct 14. pii: S0168-8278(20)33595.
    PubMed    


    September 2020
  563. HIRSCHFIELD GM, Beuers U, Kupcinskas L, Ott P, et al
    A placebo-controlled randomised trial of budesonide for primary biliary cholangitis following an insufficient response to UDCA.
    J Hepatol. 2020 Sep 17. pii: S0168-8278(20)33623.
    PubMed     Abstract available


  564. LEE-LAW PY, Olaizola P, Caballero-Camino FJ, Izquierdo-Sanchez L, et al
    Targeting UBC9-mediated protein hyper-SUMOylation in cystic cholangiocytes halts polycystic liver disease in experimental models.
    J Hepatol. 2020 Sep 17. pii: S0168-8278(20)33622.
    PubMed     Abstract available


    August 2020
  565. YOSHIZUMI T, Itoh S, Shimokawa M, Inokuchi S, et al
    Simultaneous splenectomy improves outcomes after adult living donor liver transplantation.
    J Hepatol. 2020 Aug 19. pii: S0168-8278(20)30547.
    PubMed     Abstract available


  566. LINE PD, Dueland S
    Liver transplantation for secondary liver tumors: the difficult balance between survival and recurrence.
    J Hepatol. 2020 Aug 17. pii: S0168-8278(20)30539.
    PubMed    


    July 2020
  567. DEEB M, Karlsen TH, Hirschfield GM
    The 6 C's of Primary Sclerosing Cholangitis.
    J Hepatol. 2020 Jul 7. pii: S0168-8278(20)30436.
    PubMed    


    May 2020
  568. GULFO J, Rotondo F, de Leon CGA, Cornide-Petronio ME, et al
    FGF15 improves outcomes after brain dead donor liver transplantation with steatotic and non-steatotic grafts in rats.
    J Hepatol. 2020 May 15. pii: S0168-8278(20)30299.
    PubMed     Abstract available


  569. STATTERMAYER AF, Halilbasic E, Wrba F, Ferenci P, et al
    Variants in ABCB4 (MDR3) across the spectrum of cholestatic liver diseases in adults.
    J Hepatol. 2020 May 3. pii: S0168-8278(20)30280.
    PubMed     Abstract available


    April 2020
  570. CORPECHOT C, Chazouilleres O, Belnou P, Montano-Loza AJ, et al
    Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis.
    J Hepatol. 2020 Apr 7. pii: S0168-8278(20)30205.
    PubMed     Abstract available


    March 2020
  571. CUCCHETTI A, Serenari M, Sposito C, Di Sandro S, et al
    Including mRECIST in the Metroticket 2.0 criteria improves prediction of hepatocellular carcinoma-related death after liver transplant.
    J Hepatol. 2020 Mar 19. pii: S0168-8278(20)30177.
    PubMed     Abstract available


  572. KOWDLEY KV, Vuppalanchi R, Levy C, Floreani A, et al
    A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis.
    J Hepatol. 2020 Mar 9. pii: S0168-8278(20)30160.
    PubMed     Abstract available


  573. HARRISON SA, Wai-Sun Wong V, Okanoue T, Bzowej N, et al
    Selonsertib for Patients with Bridging Fibrosis or Compensated Cirrhosis Due to NASH: Results from Randomized Ph III STELLAR Trials.
    J Hepatol. 2020 Mar 5. pii: S0168-8278(20)30126.
    PubMed     Abstract available


  574. SAVALE L, Guimas M, Ebstein N, Fertin M, et al
    Portopulmonary hypertension in the current era of pulmonary hypertension management.
    J Hepatol. 2020 Mar 4. pii: S0168-8278(20)30119.
    PubMed     Abstract available


    February 2020
  575. VAN WESSEL DBE, Thompson RJ, Gonzales E, Jankowska I, et al
    Genotype correlates with the natural history of severe bile salt export pump deficiency.
    J Hepatol. 2020 Feb 19. pii: S0168-8278(20)30105.
    PubMed     Abstract available


  576. MULLER M, Bird TG, Nault JC
    The landscape of gene mutations in cirrhosis and hepatocellular carcinoma.
    J Hepatol. 2020 Feb 7. pii: S0168-8278(20)30060.
    PubMed     Abstract available


    January 2020
  577. BAJAJ JS, Khoruts A
    Microbiota changes and Intestinal Microbiota Transplantation in Liver Diseases and Cirrhosis.
    J Hepatol. 2020 Jan 28. pii: S0168-8278(20)30058.
    PubMed     Abstract available


  578. PRAKTIKNJO M, Simon-Talero M, Romer J, Roccarina D, et al
    Total area of spontaneous portosystemic shunts independently predicts hepatic encephalopathy and mortality in liver cirrhosis.
    J Hepatol. 2020 Jan 15. pii: S0168-8278(20)30012.
    PubMed     Abstract available


  579. BASSEGODA O, Huelin P, Ariza X, Sole C, et al
    DEVELOPMENT OF CHRONIC KIDNEY DISEASE AFTER ACUTE KIDNEY INJURY IN PATIENTS WITH CIRRHOSIS IS COMMON AND IMPAIRS CLINICAL OUTCOMES.
    J Hepatol. 2020 Jan 14. pii: S0168-8278(20)30011.
    PubMed     Abstract available


    December 2019
  580. PAISANT A, Vilgrain V, Riou J, Oberti F, et al
    Comparison of extracellular and hepatobiliary MR contrast agents for the diagnosis of small HCCs.
    J Hepatol. 2019 Dec 20. pii: S0168-8278(19)30725.
    PubMed     Abstract available


  581. GARCIA-TSAO G, Bosch J, Kayali Z, Harrison SA, et al
    Randomized Placebo-Controlled Trial of Emricasan in Non-alcoholic Steatohepatitis (NASH) Cirrhosis with Severe Portal Hypertension.
    J Hepatol. 2019 Dec 20. pii: S0168-8278(19)30724.
    PubMed     Abstract available


  582. SHE S, Wu X, Zheng D, Pei X, et al
    PSMP/MSMP promotes hepatic fibrosis through CCR2 and represents a novel therapeutic target.
    J Hepatol. 2019 Dec 5. pii: S0168-8278(19)30654.
    PubMed     Abstract available


    November 2019
  583. CHIEW AL, James LP, Isbister GK, Pickering JW, et al
    Early Acetaminophen-Protein Adducts Predict Hepatotoxicity Following Overdose.
    J Hepatol. 2019 Nov 21. pii: S0168-8278(19)30677.
    PubMed     Abstract available


  584. HE X, Wang Y, Fan X, Lei N, et al
    A schistosome miRNA promotes host hepatic fibrosis by targeting transforming growth factor beta receptor III.
    J Hepatol. 2019 Nov 15. pii: S0168-8278(19)30674.
    PubMed     Abstract available


    October 2019
  585. SUNDARAM V, Kogachi S, Wong RJ, Karvellas CJ, et al
    Effect of the clinical course of acute on chronic liver failure prior to liver transplantation on post-transplant survival.
    J Hepatol. 2019 Oct 25. pii: S0168-8278(19)30640.
    PubMed     Abstract available


  586. GIANNELLI V, Roux O, Laouenan C, Manchon P, et al
    Impact of cardiac function, refractory ascites and beta blockers on the outcome of patients with cirrhosis listed for liver transplantation.
    J Hepatol. 2019 Oct 14. pii: S0168-8278(19)30603.
    PubMed     Abstract available


  587. BRIL F, Barb D, Lomonaco R, Lai J, et al
    Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis.
    J Hepatol. 2019 Oct 4. pii: S0168-8278(19)30584.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: